[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 601
1. Ripamonti CI, Easson AM, Gerdes H: Management of malignant bowel obstruction. Eur J Cancer; 2008 May;44(8):1105-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of malignant bowel obstruction.
  • Malignant bowel obstruction (MBO) is a common and distressing outcome particularly in patients with bowel or gynaecological cancer.
  • Although surgery should be the primary treatment for selected patients with MBO, it should not be undertaken routinely in patients known to have poor prognostic criteria for surgical intervention such as intra-abdominal carcinomatosis, poor performance status and massive ascites.
  • Self-expanding metallic stents are an option in malignant obstruction of the gastric outlet, proximal small bowel and colon.

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18359221.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Analgesics; 0 / Antiemetics; 0 / Gastrointestinal Agents
  •  go-up   go-down


2. Suzuki T, Yoshida K, Tanabe K, Hihara J, Ohta K, Hamai Y, Taomoto J, Toge T: [Three advanced gastric cancer patients successfully treated by combination therapy of docetaxel and TS-1]. Gan To Kagaku Ryoho; 2005 Apr;32(4):509-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Case 2: 50-year-old female with scirrhous gastric carcinoma causing huge amount of malignant ascites.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15853218.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


3. Guleng B, Tateishi K, Kanai F, Jazag A, Ohta M, Asaoka Y, Ijichi H, Tanaka Y, Imamura J, Ikenoue T, Fukushima Y, Morikane K, Miyagishi M, Taira K, Kawabe T, Omata M: Cancer-derived VEGF plays no role in malignant ascites formation in the mouse. World J Gastroenterol; 2005 Sep 21;11(35):5455-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer-derived VEGF plays no role in malignant ascites formation in the mouse.
  • AIM: Vascular endothelial growth factor (VEGF) is a potent mediator of peritoneal fluid accumulation following tumor progression.
  • This study investigated the role of VEGF secreted by cancerous cells in the formation of malignant ascites.
  • Malignant ascites formation in the mouse was analyzed by intraperitoneal injection of PancO2 cells expressing VEGF or with expression knockdown.
  • The volume of ascites following peritoneal expansion of the tumor in VEGF knockdown cells and control cells did not differ statistically in this in vivo study.
  • Moreover, the VEGF concentration in the ascites did not differ statistically.
  • CONCLUSION: Malignant ascites formation might be mediated by VEGF production in noncancerous tissues, such as stromal compartments.
  • An anti-VEGF strategy against malignant ascites could be applied to various tumors regardless of whether they secrete VEGF.
  • [MeSH-major] Ascites / etiology. Vascular Endothelial Growth Factor A / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222736.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC4320353
  •  go-up   go-down


Advertisement
4. Ripoll GV, Garona J, Hermo GA, Gomez DE, Alonso DF: Effects of the synthetic vasopressin analog desmopressin in a mouse model of colon cancer. Anticancer Res; 2010 Dec;30(12):5049-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vivo, DDAVP (2 intravenous doses of 2 μg/kg) reduced accumulation of ascites and formation of intestinal tumor nodules in mice intraperitoneally inoculated with CT-26 cells.
  • Our data suggest that DDAVP may be potentially used to minimize spread or survival of residual malignant cells during surgical procedures for colon and other gastrointestinal tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187489.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Vasopressin; ENR1LLB0FP / Deamino Arginine Vasopressin
  •  go-up   go-down


5. Caldeira A, Martin-Carreras F, Pereira E, Sousa R, Gonçalves R, Tristan J, Banhudo A: Malignant fibrous histiocytoma--a rare hepatic tumor. Rev Esp Enferm Dig; 2010 Feb;102(2):146-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma--a rare hepatic tumor.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / radiography. Liver Neoplasms / radiography
  • [MeSH-minor] Ascites / etiology. Biopsy, Needle. Fatal Outcome. Humans. Male. Middle Aged. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20361853.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] Spain
  • [Number-of-references] 2
  •  go-up   go-down


6. Katzenstein HM, Petricca S, Ricketts R, Wasilewski-Masker K, Powell C, Rapkin L, George B, Woods WG, Olson TA: Intracavitary cisplatin therapy for pediatric malignancies. Pediatr Blood Cancer; 2010 Sep;55(3):452-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PROCEDURE: From 2001 to 2009, 12 patients (1-20 years) with recurrent or unresectable malignant tumors were treated with IC-CDDP.
  • RESULTS: Malignant pleural effusions resolved in 5/7 patients.
  • No patients had ascites prior to treatment.
  • CONCLUSIONS: IC-CDDP was effective in treating malignant pleural effusions and may be a palliative option for refractory disease.
  • Long-term survival was achieved in two patients, treated at first diagnosis.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Peritoneal Neoplasms / drug therapy. Thoracic Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Ascites / drug therapy. Ascites / etiology. Child. Child, Preschool. Female. Humans. Infant. Male. Peritoneal Cavity. Pleural Cavity. Pleural Effusion, Malignant / drug therapy. Pleural Effusion, Malignant / etiology. Young Adult


7. Knezević V, Poljak M, Bradamante Z, Serman D, Levak-Svajger B, Svajger A: Yolk sac carcinoma derived from the rat epiblast as a renal isograft. Coll Antropol; 2005 Jun;29(1):189-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After prolonged (7-30 weeks) development of these teratomas as isografts, a malignant yolk sac carcinoma (YSC) developed in 45% of them.
  • It destroyed the teratoma and the recipient's kidney, metastasized to peritoneum and other sites, and caused abundant ascites containing clustered tumor cells.
  • [MeSH-minor] Animals. Ascites. Ectoderm. Embryo, Mammalian. Female. Kidney / pathology. Male. Neoplasm Metastasis. Neoplasms, Experimental. Rats. Transplants

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16117321.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Croatia
  •  go-up   go-down


8. Pietzner K, Noske A, Cho CH, Kiecker F, Sehouli J: Amelanotic metastasis of melanoma mimicking ovarian cancer: a case report and review of the literature. Anticancer Res; 2008 Jan-Feb;28(1B):563-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on a 35-year-old female patient who presented with bilateral adnexal masses, as well as massive ascites.
  • She was histologically diagnosed with malignant ovarian tumour and was referred for radical surgery.
  • Despite the variety of this case, clinicians should be aware of this differential diagnosis when treating ovarian cancer.
  • This report discusses the differential diagnosis and clinical management of both metastatic amelanotic malignant melanoma of the ovary and epithelial ovarian cancer.
  • [MeSH-major] Melanoma, Amelanotic / secondary. Ovarian Neoplasms / diagnosis. Skin Neoplasms / secondary
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18383903.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


9. Keen A, Fitzgerald D, Bryant A, Dickinson HO: Management of drainage for malignant ascites in gynaecological cancer. Cochrane Database Syst Rev; 2010;(1):CD007794
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of drainage for malignant ascites in gynaecological cancer.
  • BACKGROUND: Most patients with advanced ovarian cancer and some patients with advanced endometrial cancer need repeated drainage for malignant ascites.
  • Guidelines to advise those involved in the drainage of ascites are usually produced locally and are generally not evidence-based but mainly based on clinicians' anecdotal evidence and experience.
  • OBJECTIVES: To evaluate the benefit and harms of different practices in the management of drains for malignant ascites in the care of women with advanced or recurrent gynaecological cancer.
  • SELECTION CRITERIA: We searched for randomised controlled trials (RCTs), quasi-RCTs and non-randomised studies that compared a range of interventions for management of multiple paracentesis in women with malignant ascites who had a confirmed histological diagnosis of gynaecological cancer.
  • AUTHORS' CONCLUSIONS: Since no relevant studies were identified, we are unable to make recommendations regarding the management of drains for malignant ascites in women with gynaecological cancer.
  • [MeSH-major] Ascites / therapy. Drainage / methods. Genital Neoplasms, Female / complications

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2005 Apr;16(4):640-7 [15684225.001]
  • [Cites] J Med Assoc Thai. 1999 Jan;82(1):15-9 [10087733.001]
  • [Cites] Eur J Cancer. 2006 Mar;42(5):589-97 [16434188.001]
  • [Cites] J Palliat Med. 2006 Dec;9(6):1264-70 [17187534.001]
  • [Cites] Ann Oncol. 2007 May;18(5):945-9 [17298959.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2348-57 [17505860.001]
  • [Cites] Ann Acad Med Singapore. 2008 Jul;37(7):621-2 [18695781.001]
  • [Cites] Curr Treat Options Oncol. 2008 Jun;9(2-3):215-33 [18777213.001]
  • [Cites] J Vasc Interv Radiol. 2008 Dec;19(12):1723-31 [18951041.001]
  • [Cites] Palliat Med. 2002 May;16(3):213-8 [12046997.001]
  • [Cites] Can J Oncol. 1996 Nov;6(2):474-80 [12056099.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):557-60 [12958120.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):999-1011 [15194082.001]
  • [Cites] J Vasc Interv Radiol. 2004 Oct;15(10):1129-31 [15466800.001]
  • [Cites] Am J Obstet Gynecol. 1981 Dec 1;141(7):843-5 [7315911.001]
  • [Cites] J Surg Oncol. 1982 Aug;20(4):238-42 [6180252.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Apr 7;288(6423):1041 [6423185.001]
  • [Cites] Ann Surg. 1986 Jun;203(6):644-51 [3718029.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] J Pak Med Assoc. 1991 Feb;41(2):38-40 [1902531.001]
  • [Cites] Am Fam Physician. 1997 Jun;55(8):2612 [9191450.001]
  • [Cites] J Clin Epidemiol. 1997 Jun;50(6):683-91 [9250266.001]
  • [Cites] J Pain Symptom Manage. 1998 Aug;16(2):96-101 [9737100.001]
  • [Cites] Palliat Med. 2006 Jan;20(1):1-2 [16482751.001]
  • (PMID = 20091648.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 32
  • [Other-IDs] NLM/ EMS58190; NLM/ PMC4170997
  •  go-up   go-down


10. Buyukberber M, Koruk M, Savas MC, Gulsen MT, Pehlivan Y, Deveci R, Sevinc A, Gergerlioglu S: Leptin levels in the differential diagnosis between benign and malignant ascites. World J Gastroenterol; 2007 Jan 21;13(3):398-402
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin levels in the differential diagnosis between benign and malignant ascites.
  • AIM: To evaluate the role of leptin levels in the differential diagnosis of ascites.
  • METHODS: Ascitic leptin, TNFalpha and serum leptin levels were measured in 77 patients with ascites (35 with malignancies, 30 cirrhosis and 12 tuberculosis).
  • Peritoneal biopsy, ascites cytology and cultures or biochemical values were used for the diagnosis of patients.
  • RESULTS: In patients with malignancies, the mean serum and ascites leptin levels and their ratios were significantly decreased compared to the other patient groups and controls.
  • In tuberculosis peritonitis, ascitic fluid TNFalpha levels were significantly higher than malignant ascites and cirrhotic sterile ascites.
  • CONCLUSION: In patients with malignant ascites, levels of leptin and TNFalpha were significantly lower than in patients with tuberculous ascites.
  • [MeSH-major] Ascites / diagnosis. Leptin / metabolism
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Prospective Studies. Tumor Necrosis Factor-alpha / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 2000 Jul;33(1):33-7 [10905583.001]
  • [Cites] Leuk Lymphoma. 2006 Mar;47(3):565-8 [16396783.001]
  • [Cites] Horm Res. 1999;52(6):279-83 [10965207.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 May;13(5):581-5 [11396540.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):316-8 [11606091.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):758-63 [11836317.001]
  • [Cites] Endocr Res. 2003 Aug;29(3):257-64 [14535627.001]
  • [Cites] J Viral Hepat. 2004 Jan;11(1):91-6 [14738564.001]
  • [Cites] Respirology. 2004 Mar;9(1):81-6 [14982607.001]
  • [Cites] Dig Dis Sci. 2004 Feb;49(2):275-80 [15104370.001]
  • [Cites] BMC Gastroenterol. 2004 Sep 23;4:23 [15387890.001]
  • [Cites] Br J Surg. 1973 Aug;60(8):646-9 [4541913.001]
  • [Cites] Med Sci Sports Exerc. 1980;12(3):175-81 [7402053.001]
  • [Cites] Hepatology. 1992 May;15(5):782-94 [1568718.001]
  • [Cites] N Engl J Med. 1996 Feb 1;334(5):292-5 [8532024.001]
  • [Cites] J Clin Invest. 1996 May 1;97(9):2152-7 [8621806.001]
  • [Cites] J Exp Med. 1997 Jan 6;185(1):171-5 [8996253.001]
  • [Cites] Eur J Med Res. 1997 Jan;2(1):7-13 [9049588.001]
  • [Cites] J Biol Chem. 1997 Mar 7;272(10):6093-6 [9102398.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Apr;82(4):1293-300 [9100610.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2777-82 [9389742.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Dec;82(12):4080-2 [9398717.001]
  • [Cites] Hepatology. 1998 Feb;27(2):346-50 [9462629.001]
  • [Cites] Int J Cancer. 1998 Mar 30;76(1):25-8 [9533757.001]
  • [Cites] Hepatology. 1998 May;27(5):1227-32 [9581675.001]
  • [Cites] Alcohol Clin Exp Res. 1998 Aug;22(5 Suppl):231S-237S [9727642.001]
  • [Cites] Gastroenterology. 1998 Oct;115(4):947-53 [9753498.001]
  • [Cites] Nature. 1998 Oct 22;395(6704):763-70 [9796811.001]
  • [Cites] Int J Obes Relat Metab Disord. 1998 Dec;22(12):1234-8 [9877260.001]
  • [Cites] Int J Cancer. 1999 Feb 9;80(4):523-6 [9935151.001]
  • [Cites] Int J Obes Relat Metab Disord. 1999 Feb;23 Suppl 1:29-36 [10193859.001]
  • [Cites] Ann Intern Med. 1999 Apr 20;130(8):671-80 [10215564.001]
  • [Cites] Hepatology. 1999 Jun;29(6):1818-24 [10347125.001]
  • [Cites] J Natl Med Assoc. 2005 Jan;97(1):79-84 [15719876.001]
  • [Cites] J Hepatol. 2000 Jul;33(1):38-42 [10905584.001]
  • (PMID = 17230608.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Leptin; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ PMC4065894
  •  go-up   go-down


11. von Gruenigen V, Daly B, Gibbons H, Hutchins J, Green A: Indicators of survival duration in ovarian cancer and implications for aggressiveness of care. Cancer; 2008 May 15;112(10):2221-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Significant clinical events (SCE) were defined as ascites, bowel obstruction, and pleural effusion.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cancer Care Facilities. Chemotherapy, Adjuvant. Emergency Treatment. Female. Hospitalization. Humans. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Palliative Care. Pleural Effusion, Malignant / etiology. Pleural Effusion, Malignant / pathology. Postoperative Complications. Remission Induction. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2008 American Cancer Society.
  • (PMID = 18348300.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


12. Boulanger E, Gérard L, Gabarre J, Molina JM, Rapp C, Abino JF, Cadranel J, Chevret S, Oksenhendler E: Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol; 2005 Jul 1;23(19):4372-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS.
  • PURPOSE: Primary effusion lymphoma (PEL) is a rare high-grade B-cell non-Hodgkin's lymphoma associated with Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 (KSHV/HHV-8) infection, and is mostly observed in the course of HIV infection.
  • In a multivariate analysis, only a performance status more than 2 (hazard ratio, 5.84; 95% CI, 1.76 to 19.33) and the absence of highly active antiretroviral therapy (HAART) before PEL diagnosis (hazard ratio, 3.26; 95% CI, 1.14 to 9.34) were found to be independent predictors for shorter survival.
  • CONCLUSION: Based on a retrospective series of 28 patients, two prognostic factors were identified as being independently associated with impaired clinical outcome in HIV-related PEL--(1) a poor performance status and (2) the absence of HAART before PEL diagnosis.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome. Adult. Aged. Ascites / complications. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pericardial Effusion / complications. Pleural Effusion, Malignant / complications. Prognosis. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Outcome


13. Iwase S, Murakami T, Saito Y, Nakagawa K: Preliminary statistical assessment of intervention by a palliative care team working in a Japanese general inpatient unit. Am J Hosp Palliat Care; 2007 Feb-Mar;24(1):29-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the study, 316 consecutive patients with malignant tumor disease were referred to the palliative care team, which assessed 11 physical symptoms.
  • (3) mouth dryness, anorexia, constipation, diarrhea, fatigue, and ascites are difficult to alleviate in the long term even with palliative intervention.

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17347502.001).
  • [ISSN] 1049-9091
  • [Journal-full-title] The American journal of hospice & palliative care
  • [ISO-abbreviation] Am J Hosp Palliat Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Martín-Rufián M, Segura JA, Lobo C, Matés JM, Márquez J, Alonso FJ: Identification of genes downregulated in tumor cells expressing antisense glutaminase mRNA by differential display. Cancer Biol Ther; 2006 Jan;5(1):54-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ehrlich ascites tumor cells (EATC) is a highly proliferative malignant cell line derived from mouse mammary epithelia, whereas their derivative, 0.28AS-2 cells, expressing antisense glutaminase mRNA, show a less transformed phenotype and loss of their tumorigenic capacity in vivo correlated with an inhibition of glutaminase expression.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16294018.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / RNA, Antisense; 0 / RNA, Messenger; EC 3.5.1.2 / Glutaminase
  •  go-up   go-down


15. Chen R, Alvero AB, Silasi DA, Kelly MG, Fest S, Visintin I, Leiser A, Schwartz PE, Rutherford T, Mor G: Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. Oncogene; 2008 Aug 7;27(34):4712-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using EOC cells isolated from malignant ovarian cancer ascites and solid tumors, we identified IKKbeta as a major factor promoting a functional TLR-MyD88-NF-kappaB pathway that confers to EOC cell the capacity to constitutively secrete proinflammatory/protumor cytokines and therefore promoting tumor progression and chemoresistance.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):540-50 [15229479.001]
  • [Cites] Science. 2007 Jul 6;317(5834):124-7 [17615359.001]
  • [Cites] Cell. 2004 Aug 6;118(3):285-96 [15294155.001]
  • [Cites] Biochem Pharmacol. 2004 Sep 15;68(6):1071-80 [15313403.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):461-6 [15329734.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):405-6 [15385993.001]
  • [Cites] Cancer Res. 1994 Feb 1;54(3):724-9 [8306334.001]
  • [Cites] Nucleic Acids Res. 1995 Sep 11;23(17):3539-46 [7567467.001]
  • [Cites] Mol Cell Biol. 1999 Feb;19(2):1526-38 [9891086.001]
  • [Cites] Science. 1999 Apr 9;284(5412):321-5 [10195897.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2351-62 [15476283.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):99-104 [15615857.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):297-309 [15803156.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 May;288(5):G1055-65 [15826931.001]
  • [Cites] Cell. 2005 Jul 1;121(7):977-90 [15989949.001]
  • [Cites] J Clin Invest. 2005 Oct;115(10):2625-32 [16200195.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3810-8 [11325857.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4526-35 [11389085.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4901-9 [11406569.001]
  • [Cites] Cancer Lett. 2001 Oct 10;171(2):165-72 [11520600.001]
  • [Cites] Cancer Treat Res. 2002;107:99-118 [11775463.001]
  • [Cites] Sci STKE. 1999 Oct 26;1999(5):RE1 [11865184.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):301-10 [12001991.001]
  • [Cites] Cytokine. 2002 Mar 7;17(5):234-42 [12027404.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2062-71 [12357358.001]
  • [Cites] Nat Rev Immunol. 2002 Oct;2(10):725-34 [12360211.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Oncogene. 2003 May 1;22(17):2611-20 [12730675.001]
  • [Cites] Cell. 2003 Jul 25;114(2):148-50 [12887914.001]
  • [Cites] Nat Rev Immunol. 2003 Sep;3(9):745-56 [12949498.001]
  • [Cites] Immunity. 2003 Nov;19(5):725-37 [14614859.001]
  • [Cites] Cancer Lett. 2004 Apr 8;206(2):193-9 [15013524.001]
  • [Cites] Cell. 2004 Apr 16;117(2):225-37 [15084260.001]
  • [Cites] J Soc Gynecol Investig. 2004 May;11(4):252-9 [15120700.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1173-9 [16244651.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3859-68 [16585214.001]
  • [Cites] Sci STKE. 2006 Oct 17;2006(357):re13 [17047224.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17202-7 [17079494.001]
  • [Cites] Mol Pharmacol. 2006 Dec;70(6):1946-55 [16940413.001]
  • [Cites] Am J Reprod Immunol. 2007 Feb;57(2):93-107 [17217363.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cell. 2004 Jul 23;118(2):229-41 [15260992.001]
  • (PMID = 18408758.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA127913-01A2; United States / NCI NIH HHS / CA / R01 CA118678; United States / NCI NIH HHS / CA / R01 CA118678-02; United States / NCI NIH HHS / CA / CA127913-01A2; United States / NCI NIH HHS / CA / CA127913-02; United States / NCI NIH HHS / CA / R01 CA127913; United States / NCI NIH HHS / CA / CA118678-02; United States / NCI NIH HHS / CA / R01 CA127913-02
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / NF-kappa B; 0 / mirn199 microRNA, human; EC 2.7.11.10 / I-kappa B Kinase
  • [Other-IDs] NLM/ NIHMS263797; NLM/ PMC3041589
  •  go-up   go-down


16. Torrejón Reyes PN, Frisancho O, Gómez A, Yábar A: [Malignant peritoneal mesothelioma]. Rev Gastroenterol Peru; 2010 Jan-Mar;30(1):82-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peritoneal mesothelioma].
  • [Transliterated title] Mesotelioma Peritoneal Maligno.
  • The peritoneal mesothelioma is a rare pathology with unspecific symptoms reason to be a difficult diagnosis.
  • The abdomen distended by ascites, not painful, liver and spleen not examined.
  • Thoracic-abdominal CT: left side pleural effusion, severe ascites with thick epyplon.
  • The finds of the laparoscopy were interpreted like carcinomatosis or peritoneal tuberculosis.
  • The report of the peritoneal biopsy was informed as suggestive of undifferentiated carcinoma; the reappraisal with inmunohystochemic (calretinin +,cytokeratin +, vimentin +) indicated malignant peritoneal mesothelioma, type epithelial.
  • The malignant mesothelioma peritoneal is a unfrequent entity, with limited therapeutic options; generally detected late, with a palliative treatment.
  • [MeSH-major] Mesothelioma. Peritoneal Neoplasms

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20445731.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Peru
  •  go-up   go-down


17. Que Y, Wang X, Liu Y, Li P, Ou G, Zhao W: Ultrasound-guided biopsy of greater omentum: an effective method to trace the origin of unclear ascites. Eur J Radiol; 2009 May;70(2):331-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasound-guided biopsy of greater omentum: an effective method to trace the origin of unclear ascites.
  • OBJECTIVES: Thickened greater omentum is encountered with high frequency in patients with ascites.
  • The purpose of our study was to assess the utility of greater omentum biopsy under the guidance of ultrasound (US) in tracing the origin of unclear ascites and differentiating benign and malignant ascites.
  • One hundred and ninety-four patients with unclear ascites and thickened greater omentum were included in the study.
  • The sonograms of greater omentum were evaluated before undergoing the ultrasound-guided biopsy and a biopsy was considered successful if a specific benign or malignant diagnosis was rendered by the pathologist.
  • RESULTS: Successful biopsy was rendered for 182 biopsy procedures (93.8%, 182/194) including tuberculosis (n=114), chronic inflammation (n=3), metastases (n=58), malignant mesothelioma (n=6) and pseudomyxoma peritonei (n=1).
  • According to the results of biopsy and follow-up, the sensitivity and specificity of biopsy in distinguishing malignant ascites from benign ascities were respectively 95.6% (65/68) and 92.9% (117/126).
  • No "cerebral fissure" sign was observed in peritoneal carcinomatosis.
  • Moreover, if the specific "cerebral fissure" sign was combined with the biopsy results, the specificity of biopsy in distinguishing malignant ascites from benign ascits increased to 96.8% (122/126).
  • CONCLUSION: Ultrasound-guided biopsy of greater omentum is an important and effective method to diagnose the unclear ascites for patients with thickened omentum if certain techniques could be paid attention to.
  • "Cerebral fissure" sign of greater omentum was a specific sign in indicating the tuberculous peritonitis and could increase the specificity of biopsy in distinguishing malignant ascites from benign ascits if combined with the biopsy results.
  • [MeSH-major] Ascites / pathology. Ascites / ultrasonography. Biopsy, Needle / methods. Omentum / pathology. Omentum / ultrasonography. Peritoneal Diseases / pathology. Peritoneal Diseases / ultrasonography. Ultrasonography, Interventional / methods

  • MedlinePlus Health Information. consumer health - Peritoneal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18328658.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


18. Yildirim B, Sari R, Isci N: Patients with spontaneous bacterial peritonitis, and malignant and cirrhotic ascites. J Natl Med Assoc; 2005 Feb;97(2):276-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with spontaneous bacterial peritonitis, and malignant and cirrhotic ascites.
  • BACKGROUND: Cytokines play a key role in the regulation of cells of the immune system and also have been implicated in the pathogenesis of malignant diseases.
  • METHOD AND PATIENTS: We studied tumor necrosis factor-alpha, tumor necrosis factor receptor and C-reactive protein levels in both ascitic fluid and serum in patients with spontaneous bacterial peritonitis (SBP) (n = 22), and in the malignant (n = 38) and cirrhotic (n = 32) ascites.
  • RESULTS: C-reactive protein, tumor necrosis factor-alpha and tumor necrosis factor receptor levels in the ascitic fluid were found to be elevated in the SBP (p < 0.001) and malignant groups (p < 0.005) when compared with the sterile cirrhotic group.
  • C-reactive protein levels in the serum were found to be elevated in the SBP group when compared with the sterile cirrhotic (p < 0.001) and malignant group (p < 0.005).
  • Tumor necrosis factor-alpha in the serum was significantly elevated in the SBP when compared with the cirrhotic (p < 0.005) and malignant ascites (p < 0.001).
  • Sensitivity and specificity of ascitic fluid CRP in discriminating malignant 84% and 67% and SBP from sterile ascites were 90% and 76%, respectively.
  • Sensitivity and specificity of ascitic fluid TNF-alpha in discriminating malignant 77% and 60% and SBP from sterile ascites were 82% and 66%, respectively.
  • Sensitivity and specificity of TNF-r p60 in discriminating malignant 74% and 70% and SBP from sterile ascites were 80% and 76%, respectively.
  • Ascitic fluid Creactive protein to differentiate SBP and malignant ascitic from cirrhotic ascites are cheap, practical and safe tests used in the differential diagnosis of ascites.
  • [MeSH-major] Ascites / blood. Ascitic Fluid / metabolism. C-Reactive Protein / metabolism. Liver Cirrhosis / blood. Liver Neoplasms / blood. Peritonitis / blood. Peritonitis / microbiology. Receptors, Tumor Necrosis Factor / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1990 Jun 15;112(12):917-20 [2339855.001]
  • [Cites] Lancet. 1992 Jan 11;339(8785):89-91 [1345871.001]
  • [Cites] Adv Intern Med. 1992;37:313-36 [1558000.001]
  • [Cites] Immunol Today. 1992 Apr;13(4):122-5 [1580993.001]
  • [Cites] Hepatology. 1992 Sep;16(3):749-55 [1324217.001]
  • [Cites] Kidney Int. 1993 Jan;43(1):226-33 [8433563.001]
  • [Cites] Clin Infect Dis. 1993 Aug;17(2):218-23 [7980730.001]
  • [Cites] Cancer. 1993 Oct 15;72(8):2433-40 [8402460.001]
  • [Cites] Eur J Clin Invest. 1993 Dec;23(12):832-6 [7511536.001]
  • [Cites] Cytokine. 1995 Jan;7(1):26-38 [7749064.001]
  • [Cites] Liver. 1995 Oct;15(5):265-70 [8531597.001]
  • [Cites] Hepatology. 1998 May;27(5):1227-32 [9581675.001]
  • [Cites] J Pediatr. 1981 Sep;99(3):365-9 [7264788.001]
  • [Cites] Clin Exp Immunol. 1984 Jun;56(3):669-76 [6235072.001]
  • [Cites] Hepatology. 1985 May-Jun;5(3):457-62 [3888810.001]
  • [Cites] Dis Mon. 1985 Sep;31(9):1-48 [3899555.001]
  • [Cites] Am J Clin Pathol. 1986 Dec;86(6):773-5 [3788865.001]
  • [Cites] Gut. 1987 May;28(5):623-41 [3297941.001]
  • [Cites] J Exp Med. 1987 Jul 1;166(1):253-8 [2439635.001]
  • [Cites] J Exp Med. 1987 Oct 1;166(4):1132-7 [3309124.001]
  • [Cites] Lancet. 1988 Jul 9;2(8602):72-4 [2898700.001]
  • [Cites] Cancer. 1989 Apr 15;63(8):1567-71 [2466549.001]
  • [Cites] Surg Gynecol Obstet. 1990 Jan;170(1):32-8 [2294627.001]
  • [Cites] J Clin Invest. 1990 Nov;86(5):1396-1402 [2173717.001]
  • [Cites] Hepatology. 1991 Feb;13(2):364-75 [1995444.001]
  • [Cites] Semin Arthritis Rheum. 1990 Dec;20(3):129-47 [1705051.001]
  • [Cites] J Immunol. 1991 May 1;146(9):3032-7 [1707930.001]
  • [Cites] J Immunol. 1990 Oct 15;145(8):2507-13 [2170518.001]
  • (PMID = 15712792.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; 9007-41-4 / C-Reactive Protein
  • [Other-IDs] NLM/ PMC2568775
  •  go-up   go-down


19. Demotte N, Wieërs G, Van Der Smissen P, Moser M, Schmidt C, Thielemans K, Squifflet JL, Weynand B, Carrasco J, Lurquin C, Courtoy PJ, van der Bruggen P: A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res; 2010 Oct 1;70(19):7476-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animals. Ascites / immunology. Ascites / pathology. Breast Neoplasms / immunology. Breast Neoplasms / pathology. Breast Neoplasms / therapy. Cancer Vaccines / immunology. Cancer Vaccines / pharmacology. Cell Line, Tumor. Female. Humans. Interferon-gamma / immunology. Interferon-gamma / secretion. Ligands. Mastocytoma / drug therapy. Mastocytoma / immunology. Melanoma / immunology. Melanoma / pathology. Melanoma / therapy. Mice. Pleural Effusion, Malignant / immunology. Pleural Effusion, Malignant / pathology. Receptors, Antigen, T-Cell / immunology

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 AACR.
  • (PMID = 20719885.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Sugars; 0 / Cancer Vaccines; 0 / GCS-100; 0 / Galectin 3; 0 / Ligands; 0 / Polysaccharides; 0 / Receptors, Antigen, T-Cell; 3Y5B2K5OOK / N-acetyllactosamine; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


20. Popescu I, Sîrbu-Boeţi MP, Tomulescu V, Ciurea S, Boroş M, Hrehoreţ D, Jemna C: [Therapy of malignant liver tumors using microwave and radiofrequency ablation]. Chirurgia (Bucur); 2005 Mar-Apr;100(2):111-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy of malignant liver tumors using microwave and radiofrequency ablation].
  • [Transliterated title] Terapia tumorilor hepatice maligne cu microunde şi unde de radiofrecvenţă.
  • The aim of our study was to evaluate the efficiency for thermo-ablation with microwave and radiofrequency on patients with malignant liver tumors.
  • The diagnosis was hepatocarcinoma in 38 patients (72%), liver metastases from colorectal cancer in 9 (17%) and from non-colorectal cancer (6-11%).
  • The encountered complications were ascites, right pleural effusion and liver abscesses.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15957451.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


21. Oh SY, Kwon HC, Lee S, Lee DM, Yoo HS, Kim SH, Jang JS, Kim MC, Jeong JS, Kim HJ: A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. Jpn J Clin Oncol; 2007 Dec;37(12):930-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
  • BACKGROUND: Clinical studies regarding chemotherapy for gastric cancer patients with malignant ascites have been classically rather limited in scope, largely because peritoneal seeding produces no measurable lesions, and patients generally exhibited poor performance status.
  • METHODS: Gastric cancer patients with cytologically confirmed malignant ascites were treated with cycles of oxaliplatin at 85 mg/m(2) plus leucovorin 20 mg/m(2) on the first day of treatment, followed by 5-fluorouracil (5-FU) via a 400 mg/m(2) bolus and a 22 h continuous infusion of 600 mg/m(2) 5-FU on Days 1-2 at 2-week intervals.
  • Decreases or disappearances of ascites levels were observed in 17 (35.4%) patients.
  • CONCLUSION: The m-FOLFOX-4 regimen utilized herein was determined to be both safe and feasible even for gastric cancer patients with malignant ascites in poor performance status.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Ascites / etiology. Carcinoma / drug therapy. Palliative Care / methods. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18211984.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Kalantri Y, Naik G, Joshi SP, Jain A, Phatak S, Chavan R, Hemvani N, Chitnis DS: Role of cancer antigen-125 from pleural & ascitic fluid samples in non malignant conditions. Indian J Med Res; 2007 Jan;125(1):25-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of cancer antigen-125 from pleural & ascitic fluid samples in non malignant conditions.
  • BACKGROUND & OBJECTIVE: CA-125, an ovarian tumor marker is known to increase in non malignant conditions such as tubercular and non tubercular pleuritis and ascites.
  • We undertook this study to evaluate non-specific rise in CA-125 levels in conditions associated with pleural effusion and ascites and also to understand the mechanism of its secretion.
  • METHODS: CA-125 levels in 38 pleural and 46 ascitic fluid samples from non malignant cases and 10 blood samples from pulmonary tuberculosis cases were estimated by ELISA.
  • [MeSH-major] Ascitic Fluid / chemistry. CA-125 Antigen / analysis. Pleural Effusion / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Indian J Med Res. 2007 Jan;125(1):10-2 [17332651.001]
  • (PMID = 17332654.001).
  • [ISSN] 0971-5916
  • [Journal-full-title] The Indian journal of medical research
  • [ISO-abbreviation] Indian J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


23. Sucher R, Schroecksnadel K, Weiss G, Margreiter R, Fuchs D, Brandacher G: Neopterin, a prognostic marker in human malignancies. Cancer Lett; 2010 Jan 1;287(1):13-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increased neopterin concentrations are established in patients with an activated cellular (= Th1-type) immune response which includes allograft rejection, viral infection and autoimmune disorders as well as various malignant tumors.
  • In patients with several types of cancer, neopterin concentrations in body fluids like urine, serum/plasma or ascites parallel the course of the disease, and a higher neopterin concentration in patients is an independent predictor of a shorter survival period.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Tryptophan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19500901.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / Reactive Oxygen Species; 670-65-5 / Neopterin; 8DUH1N11BX / Tryptophan
  • [Number-of-references] 132
  •  go-up   go-down


24. Koc S, Beydilli G, Tulunay G, Ocalan R, Boran N, Ozgul N, Kose MF, Erdogan Z: Peritoneal tuberculosis mimicking advanced ovarian cancer: a retrospective review of 22 cases. Gynecol Oncol; 2006 Nov;103(2):565-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal tuberculosis mimicking advanced ovarian cancer: a retrospective review of 22 cases.
  • OBJECTIVE: To evaluate the clinical, laboratory and diagnostic features in women with peritoneal tuberculosis that resembled advanced ovarian malignancy.
  • METHODS: A retrospective review of women with peritoneal tuberculosis who were managed at TCSB Ankara Etlik Maternity and Women's Health Teaching and Research Hospital from July 1992 to November 2004 was undertaken.
  • RESULTS: Among the 1,826 women treated during the study period, 22 women with peritoneal tuberculosis (1.2%) were identified.
  • All patients with peritoneal tuberculosis had ascites, 20 patients (90.91%) had elevated CA125 levels and 17 patients (77.27%) had detectable pelvic masses in the preoperative period.
  • Frozen section was performed in 15 patients and revealed chronic granulomatous changes and final pathological examination confirmed the diagnosis.
  • CONCLUSION: Our data indicate that the majority of the cases with peritoneal tuberculosis can be diagnosed intraoperatively through the use of frozen section in conjunction with clinical features.
  • Ascites and high levels of Ca125 do not necessarily indicate that the clinical picture is malignant in reproductive women.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Peritonitis, Tuberculous / diagnosis
  • [MeSH-minor] Adult. Aged. Biopsy. CA-125 Antigen / blood. Diagnosis, Differential. Female. Humans. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed


25. Ding LW, Lai CC, Lee LN, Hsueh PR: Abdominal nontuberculous mycobacterial infection in a university hospital in Taiwan from 1997 to 2003. J Formos Med Assoc; 2006 May;105(5):370-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Continuous ambulatory peritoneal dialysis (CAPD)-associated peritonitis is the most common manifestation of infection due to nontuberculous mycobacteria (NTM).
  • METHODS: The medical records of all patients with a diagnosis of abdominal NTM infection from January 1997 through to December 2003 were retrospectively reviewed.
  • The peritoneal fluid appearance varied considerably, with no particular predominance of clear, turbid, bloody, or chylous findings.
  • Seven patients (64%) died before diagnosis.
  • CONCLUSION: Abdominal NTM infection is frequently overlooked because of its rarity and nonspecific symptoms, with consequent delays in diagnosis and treatment.
  • In immunocompromised patients with ascites from any cause (liver cirrhosis, malignant ascites, etc.
  • ), NTM peritonitis should be considered early in the differential diagnosis of symptoms including fever, abdominal pain and weight loss.

  • MedlinePlus Health Information. consumer health - Mycobacterial Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16638646.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


26. Kitayama J, Ishigami H, Kaisaki S, Hidemura A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita H, Nagawa H: Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer. Oncology; 2010;78(1):40-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer.
  • Malignant ascites caused by gastric cancer are chemotherapy resistant and carry a poor prognosis.
  • The efficacy of a regimen including intraperitoneal paclitaxel (PTX) was evaluated in 33 gastric cancer patients with ascetic fluid in the peritoneal cavity diagnosed with computed tomography (CT) scanning.
  • Ascites disappeared completely in 8 patients and were markedly reduced (to <3% of the original volume) in 4 of the 9 patients (44%) who initially had massive (>2,500 ml) ascites.
  • Weekly intravenous and intraperitoneal PTX combined with S-1 was highly effective in gastric cancer with malignant ascites.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Ascites / drug therapy. Peritoneal Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20197706.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


27. Salman MC, Basaran A, Guler T, Gultekin M, Dursun P, Karcaaltincaba M, Kes S, Ayhan A: Meigs' syndrome with highly elevated ca. 125 levels in a patient with Takayasu arteritis: a case report. Arch Gynecol Obstet; 2005 Jun;272(1):90-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An evaluation of abdomen and pelvis showed ascites and a solid mass.
  • [MeSH-major] CA-125 Antigen / blood. Fibroma / diagnosis. Meigs Syndrome / diagnosis. Takayasu Arteritis / diagnosis
  • [MeSH-minor] Angiography. Ascites / etiology. Diagnosis, Differential. Female. Humans. Middle Aged. Pleural Effusion, Malignant / etiology. Postmenopause. Subclavian Artery / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Takayasu arteritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15815942.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


28. Rezaei Kalantari H: [Malignant peritoneal mesothelioma: a case report]. Rev Med Liege; 2010 Sep;65(9):490-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peritoneal mesothelioma: a case report].
  • [Transliterated title] Le cas clinique du mois. Mésothéliome péritonéal malin.
  • I report two cases of malignant peritoneal mesothelioma.
  • In both cases the diagnosis was establishes through both biopsy conducted by laparoscopy and ascites fluid cytology.
  • Prognosis for patients with malignant peritoneal mesothelioma is very poor with a mean survival of 5,4 months versus 12.5 months for pleural mesothelioma.
  • Peritoneal mesothelioma, although rare, should be considered among the differential diagnosis of ascites differential diagnosis work up.
  • [MeSH-major] Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086578.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


29. Yang HJ, Kim TH, Park MK, Lim CH, Lee KH, Kim CW, Han SW, Kim JA: [A case of primary extragastrointestinal stromal tumor presenting as peritoneal dissemination]. Korean J Gastroenterol; 2010 Nov;56(5):319-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of primary extragastrointestinal stromal tumor presenting as peritoneal dissemination].
  • We experienced a 70-year-old man with primary EGIST presenting as peritoneal dissemination.
  • Abdominal CT showed diffuse peritoneal thickening with a large amount of ascites, but no definite mass lesion.
  • On account of unresectability and histologic parameters of malignant behavior, he was started on imatinib.
  • [MeSH-major] Gastrointestinal Stromal Tumors / diagnosis. Peritoneal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21099240.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD34; 0 / Vimentin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


31. Sinkovics JG, Horvath JC: Human natural killer cells: a comprehensive review. Int J Oncol; 2005 Jul;27(1):5-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A patient with malignant ascites due to ovarian carcinoma entered remission on LAK cell therapy.
  • Just as dendritic cells, the major antigen presentors, may undergo malignant transformation, NK cells are also subject to transformation into FasL-producer virulent lymphoma-leukemia cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942642.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 585
  •  go-up   go-down


32. Timmerman D, Testa AC, Bourne T, Ferrazzi E, Ameye L, Konstantinovic ML, Van Calster B, Collins WP, Vergote I, Van Huffel S, Valentin L, International Ovarian Tumor Analysis Group: Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. J Clin Oncol; 2005 Dec 1;23(34):8794-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group.
  • PURPOSE: To collect data for the development of a more universally useful logistic regression model to distinguish between a malignant and benign adnexal tumor before surgery.
  • The outcome measure was the histologic classification of excised tissues as malignant or benign.
  • RESULTS: Data from 1,066 patients recruited from nine European centers were included in the analysis; 800 patients (75%) had benign tumors and 266 (25%) had malignant tumors.
  • (1) personal history of ovarian cancer, (2) hormonal therapy, (3) age, (4) maximum diameter of lesion, (5) pain, (6) ascites, (7) blood flow within a solid papillary projection, (8) presence of an entirely solid tumor, (9) maximal diameter of solid component, (10) irregular internal cyst walls, (11) acoustic shadows, and (12) a color score of intratumoral blood flow.
  • [MeSH-major] Adnexal Diseases / diagnosis. Preoperative Care / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. CA-125 Antigen / blood. Cystadenoma, Mucinous / classification. Cystadenoma, Mucinous / diagnosis. Cystadenoma, Mucinous / surgery. Cystadenoma, Papillary / classification. Cystadenoma, Papillary / diagnosis. Cystadenoma, Papillary / surgery. Cystadenoma, Serous / classification. Cystadenoma, Serous / diagnosis. Cystadenoma, Serous / surgery. Diagnosis, Differential. Female. Humans. Logistic Models. Middle Aged. Multivariate Analysis. Ovarian Cysts / classification. Ovarian Cysts / diagnosis. Ovarian Cysts / surgery. Ovarian Neoplasms / classification. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / surgery. Ovariectomy. Prospective Studies. Reproducibility of Results. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314639.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


33. Okadome M, Saito T, Tsukamoto N, Nishi K, Nishiyama N, Nagata E: Endometrial scraping cytology in women with extragenital malignancies. Acta Cytol; 2006 Mar-Apr;50(2):158-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extragenital malignant cells were detected in endometrial smears in 13 cases.
  • Both ascites and peritoneal dissemination were found in 8 cases.
  • CONCLUSION: Endometrial scraping smears are useful for detecting extragenital malignant cells that enter the uterine cavity.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / pathology. Mass Screening / methods. Neoplasms / diagnosis. Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16610683.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Schmeding M, Neumann U, Neuhaus P: Colonic metastasis of Klatskin tumor: case report and discussion of the current literature. World J Gastroenterol; 2006 Sep 7;12(33):5393-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A specimen of the ascites present preoperatively displayed no malignant cells.
  • Following laparotomy we found local peritoneal carcinosis in the ligamentum hepatoduodenale with lymphatic nodules that tested positive for cholangiocellular carcinoma in online pathological examination.
  • Histological examination of the resected sigmoid revealed transmural manifestation of a malignant neoplastic process with both a tubular and a solid growth pattern in conformity with metastasis of a Klatskin tumor.
  • Peritoneal carcinosis is a common phenomenon in the dissemination pattern of advanced-stage Klatskin tumors, yet to our knowledge this is the first case of intramural colonic growth following peritoneal metastasis.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / secondary. Klatskin Tumor / pathology

  • Genetic Alliance. consumer health - Klatskin tumor.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 Aug;230(2):266-75 [10450742.001]
  • [Cites] Hepatology. 2003 May;37(5):961-9 [12717374.001]
  • [Cites] Semin Oncol. 1988 Apr;15(2):106-15 [2835814.001]
  • [Cites] Ann Surg. 1992 Jan;215(1):31-8 [1309988.001]
  • [Cites] Ann Surg. 1991 Jan;213(1):21-5 [1845927.001]
  • [Cites] Arch Surg. 1995 Mar;130(3):270-6 [7534059.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):83-8 [7740815.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):628-38 [8916878.001]
  • [Cites] Dig Surg. 1999;16(3):209-13 [10436369.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):171-90 [8000995.001]
  • (PMID = 16981275.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4088212
  •  go-up   go-down


35. Savas B, Percinel S, Ceyhan K, Sertcelik A, Tezcan S: The development of papillary serous carcinoma of the peritoneum subsequent to endometrial carcinoma: a case report and review of the literature. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1108-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abdominal and pelvic computed tomography demonstrated ascites, omental thickening, and nodularity.
  • Paracentesis showed malignant cells resembling papillary adenocarcinoma.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986245.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Wang PC, Yang TL, Pan HB: CT images of a malignant-transformed ovarian mature cystic teratoma with rupture: a case report. Korean J Radiol; 2008 Sep-Oct;9(5):458-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT images of a malignant-transformed ovarian mature cystic teratoma with rupture: a case report.
  • A malignant transformation or a tumor rupture is a rare complication of ovarian mature cystic teratoma (MCT).
  • A tumor rupture in a malignant-transformed MCT has never been reported in the literature.
  • We present the CT images of a 39-year-old woman showing a large, predominantly cystic mass in the lower abdomen, with fat-fluid-level ascites.
  • The pathologic diagnosis of the ruptured MCT unveils the malignant transformation (squamous cell carcinoma) and mesenteric carcinomatosis.
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic / pathology. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2000 Jan;174(1):261-2 [10628494.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):475-90 [11259710.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jun;178(6):1574 [12034646.001]
  • [Cites] AJR Am J Roentgenol. 2004 Sep;183(3):743-50 [15333365.001]
  • [Cites] Am J Emerg Med. 1992 Jul;10(4):344-6 [1616524.001]
  • [Cites] Obstet Gynecol. 1959 Feb;13(2):198-203 [13633125.001]
  • [Cites] Arch Gynecol Obstet. 2004 Nov;270(3):189-91 [15526210.001]
  • [Cites] Arch Gynecol Obstet. 2005 Apr;271(4):355-7 [15551144.001]
  • (PMID = 18838856.001).
  • [ISSN] 1229-6929
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2627209
  •  go-up   go-down


37. Afshan A: Pelvic tuberculosis mimicking malignant ovarian tumour. J Coll Physicians Surg Pak; 2006 Jan;16(1):64-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic tuberculosis mimicking malignant ovarian tumour.
  • Tuberculosis is highly prevalent in developing world and should be considered in the diagnosis of pelvic mass, ascites and elevated serum CA 125 levels.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Peritonitis, Tuberculous / diagnosis
  • [MeSH-minor] Adult. Antitubercular Agents / therapeutic use. Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16441994.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


38. Gerstner ER, Duda DG, di Tomaso E, Ryg PA, Loeffler JS, Sorensen AG, Ivy P, Jain RK, Batchelor TT: VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol; 2009 Apr;6(4):229-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anti-VEGF agents might also be useful in other cancer-related conditions that increase vascular permeability, such as malignant pleural effusions or ascites.

  • Genetic Alliance. consumer health - Edema.
  • Genetic Alliance. consumer health - Brain Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333229.001).
  • [ISSN] 1759-4782
  • [Journal-full-title] Nature reviews. Clinical oncology
  • [ISO-abbreviation] Nat Rev Clin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA080124; United States / NCI NIH HHS / CA / R01 CA159258
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Quinazolines; 0 / Vascular Endothelial Growth Factor A; NQU9IPY4K9 / cediranib
  • [Number-of-references] 62
  • [Other-IDs] NLM/ NIHMS765828; NLM/ PMC4793889
  •  go-up   go-down


39. Koufuji K, Aoyagi K, Yano S, Murakami N, Miyagi M, Imaizumi T, Shirouzu K: [Peritoneal dissemination of scirrhous type 4 gastric cancers]. Gan To Kagaku Ryoho; 2005 Oct;32(10):1384-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peritoneal dissemination of scirrhous type 4 gastric cancers].
  • The essential cause of inoperability was peritoneal dissemination with malignant abdominal abscises.
  • The incidence of peritoneal dissemination was 48.2% of all resected cases.
  • Six cases with peritoneal dissemination were treated by chemotherapy with cisplatin and etoposide infused intra-peritoneally and 2 of them were diagnosed as P 0 after 4 weeks.
  • One case with type 4 gastric cancer who had right hydronephrosis and malignant abdominal ascites underwent curative resection after successful treatment with TS-1.
  • [MeSH-major] Adenocarcinoma, Scirrhous / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227734.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 6PLQ3CP4P3 / Etoposide; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


40. Choudhary S, Fasih N, Papadatos D, Surabhi VR: Unusual imaging appearances of endometriosis. AJR Am J Roentgenol; 2009 Jun;192(6):1632-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infrequent manifestations of endometriosis, including malignant degeneration, scar endometriosis, association with ascites, and invasive endometriosis, are described.
  • Familiarity with its varied presentations may allow accurate diagnosis.
  • [MeSH-major] Endometriosis / diagnosis. Laparoscopy / methods. Magnetic Resonance Imaging / methods. Ultrasonography / methods

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] AJR Am J Roentgenol. 2010 Jan;194(1):W119; author reply W120 [20028883.001]
  • (PMID = 19457828.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


41. Agelopoulou P, Kapatais A, Varounis C, Grassos C, Kalkandi E, Kouris N, Pierakeas N, Babalis D: Hepatocellular carcinoma with invasion into the right atrium. Report of two cases and review of the literature. Hepatogastroenterology; 2007 Oct-Nov;54(79):2106-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In both our cases, the patients had liver cirrhosis and were admitted to our department due to symptoms such as worsening of the jaundice, ascites and edema of the lower extremities.
  • The diagnosis of the HCC was established when we found high levels of alpha-fetoprotein, and the patients underwent MRI and CT-scan that were indicative of HCC.
  • In conclusion, when a patient with a history of chronic hepatic disease presents with symptoms of right heart failure one must be cautious and should bear in mind that right heart involvement from a malignant tumor may be present.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251169.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Number-of-references] 11
  •  go-up   go-down


42. Vysotskii MM, Digaeva MA, Kushlinskii NE, Abbasova SG, Laktionov KP, Ermilova VD, Bakhoeva KA, Kryuk YV, Manukhin IB: Serum sFas, leptin, and VEGF in patients with ovarian cancer and benign tumors. Bull Exp Biol Med; 2009 Nov;148(5):810-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The levels of sFas and leptin were virtually the same in benign and malignant ovarian tumors, while VEGF concentration was higher in patients with ovarian cancer.
  • Multifactorial analysis showed that the disease stage (p=0.006), presence of ascites (p=0.03), VEGF concentration (p=0.02), and the sFas/leptin coefficient (p=0.045) are highly significant independent factors for predicting the relapse-free survival of patients with serous ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20396799.001).
  • [ISSN] 1573-8221
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Biomarkers, Tumor; 0 / Leptin; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


43. Imaizumi T, Aoyagi K, Miyagi M, Shirouzu K: Suppressive effect of bevacizumab on peritoneal dissemination from gastric cancer in a peritoneal metastasis model. Surg Today; 2010 Sep;40(9):851-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppressive effect of bevacizumab on peritoneal dissemination from gastric cancer in a peritoneal metastasis model.
  • PURPOSE: Vascular endothelial growth factor (VEGF) has been reported to enhance vascular permeability and angiogenesis in the abdominal wall, thereby contributing to peritoneal dissemination with malignant ascites.
  • We conducted this experimental study to find out if bevacizumab, a humanized monoclonal antibody against VEGF, had a suppressive effect on peritoneal dissemination from gastric cancer, in an experimental nude mouse model of peritoneal metastasis.
  • Five mice were killed, and we measured their body weight, the mean number of tumor nodules, and the volume of ascites.
  • RESULTS: The volume of ascites and the mitotic index were significantly lower in the therapy group than in the nontherapy group (P = 0.042 and P < 0.01, respectively).
  • CONCLUSION: Bevacizumab may suppress peritoneal dissemination from gastric cancer.
  • [MeSH-major] Angiogenesis Inhibitors / administration & dosage. Antibodies, Monoclonal / administration & dosage. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Humanized. Ascites / pathology. Bevacizumab. Cell Line, Tumor. Injections, Intraperitoneal. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Mitotic Index. Neoplasm Transplantation. Vascular Endothelial Growth Factor A / immunology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Jan 1;85(1):178-87 [9921991.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Jun 15;161(2):851-8 [2735925.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5224-9 [14500349.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):622-30 [10690548.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6371-5 [18927275.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30336-43 [9804796.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):360-8 [7812969.001]
  • [Cites] Int J Clin Oncol. 2007 Feb;12(1):17-24 [17380436.001]
  • [Cites] Cancer Res. 1986 Jan;46(1):1-7 [2998604.001]
  • [Cites] J Natl Cancer Inst. 1998 Mar 18;90(6):447-54 [9521169.001]
  • [Cites] Am J Pathol. 1998 Oct;153(4):1249-56 [9777956.001]
  • [Cites] Am J Pathol. 1995 May;146(5):1029-39 [7538264.001]
  • [Cites] Science. 1983 Feb 25;219(4587):983-5 [6823562.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12 ):1979-86 [12799646.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2729-35 [17363594.001]
  • [Cites] Nat Rev Drug Discov. 2004 May;3(5):391-400 [15136787.001]
  • [Cites] Int J Oncol. 1996 Apr;8(4):795-802 [21544429.001]
  • [Cites] Gastric Cancer. 2005;8(3):155-63 [16086118.001]
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):373-8 [10379858.001]
  • [Cites] Surg Today. 2009;39(4):290-4 [19319634.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] J Biol Regul Homeost Agents. 2001 Apr-Jun;15(2):140-4 [11501971.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Dec 16;181(2):902-6 [1755866.001]
  • [Cites] J Cell Physiol. 1992 Dec;153(3):557-62 [1447317.001]
  • [Cites] Gene Ther. 2000 Jun;7(12):1027-33 [10871751.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5412-6 [10554007.001]
  • (PMID = 20740349.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


44. Bandyopadhyay R, Bandyopadhyay SK, Ghosal J, Kumar U, Dutta A: Study of biochemical parameters of ascitic fluid in exudative ascites with special reference to tuberculous peritonitis. J Indian Med Assoc; 2006 Apr;104(4):174, 176-7, 185
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of biochemical parameters of ascitic fluid in exudative ascites with special reference to tuberculous peritonitis.
  • In an attempt to differentiate between three important but clinically similar conditions of exudative ascites like tuberculous peritonitis, spontaneous bacterial peritonitis (SBP) and malignant ascites, we evaluated the biochemical parameters of ascitic fluid as a diagnostic aid.
  • The serum ascitic albumin gradient (SAAG), lactate dehydrogenase (LDH), pH, adenosine deaminase(ADA), carcino-embryonic antigen (CEA) and carbohydrate antigen (CA-125) levels were measured in 36 patients with tuberculous peritonitis, 30 patients with SBP and 30 patients with ascites due to malignant disorders.
  • The LDH level was significantly lower in tuberculous peritonitis patients than in malignant and SBP groups.
  • Elevated ascitic fluid CEA (>2 ng/ml) and CA - 125(> 35 U/l) was found exclusively in cases of malignant ascites with a single case of tuberculous peritonitis showing CA-125 value > 35 U/l.
  • [MeSH-major] Ascites. Ascitic Fluid / chemistry. Peritonitis, Tuberculous / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910322.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 3.5.4.4 / Adenosine Deaminase
  •  go-up   go-down


45. Takano M, Yoshikawa T, Kato M, Aida S, Goto T, Furuya K, Kikuchi Y: Primary clear cell carcinoma of the peritoneum: report of two cases and a review of the literature. Eur J Gynaecol Oncol; 2009;30(5):575-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common neoplasms of the peritoneum are malignant mesothelioma and serous papillary adenocarcinoma.
  • Case 2, a 66-year-old woman, presented with massive ascites and abdominal tumor.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Antineoplastic Combined Chemotherapy Protocols. Peritoneal Neoplasms / pathology

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Gynaecol Oncol. 2010;31(1):4. Yoshokawa, T [corrected to Yoshikawa, T]
  • (PMID = 19899421.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 15
  •  go-up   go-down


46. Hosoya Y, Kobayashi E, Takizawa T, Fujimura A, Yasuda Y, Nagai H, Kanazawa K: Effect of intraperitoneal neutrophils induced by OK432 on malignant ascites. Surg Today; 2005;35(1):60-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of intraperitoneal neutrophils induced by OK432 on malignant ascites.
  • PURPOSE: To evaluate the efficacy of a streptococcal preparation, OK432, on malignant ascites in mice.
  • [MeSH-major] Ascites / pathology. Neoplasm Transplantation / mortality. Neutrophils / physiology. Peritoneal Neoplasms / pathology. Picibanil / pharmacology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15622466.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cytokines; 39325-01-4 / Picibanil
  •  go-up   go-down


47. Shiau CS, Chang MY, Hsieh CC, Hsieh TT, Chiang CH: Meigs' syndrome in a young woman with a normal serum CA-125 level. Chang Gung Med J; 2005 Aug;28(8):587-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on a 27-year-old woman who presented with an ovarian solid tumor (20 x 15 cm) and massive ascites.
  • A physical examination and chest X-ray revealed a moderate amount of pleural effusion on the right side.
  • Cytologic study of the pleural effusion showed reactive mesothelial cells without evidence of malignancy.
  • An explorative laparotomy revealed approximately 1500 ml of serous ascites and a very large multilobulated left adnexal mass (20 x 15 cm) with no malignant cytology in the ascitic fluid.
  • Postoperatively, the pleural effusion spontaneously resolved, and the microscopic examination revealed a benign fibroma-thecoma, confirming the diagnosis of Meigs' syndrome.
  • [MeSH-minor] Adult. Female. Humans. Pleural Effusion / diagnosis

  • Genetic Alliance. consumer health - Young syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16265850.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


48. Murugan P, Siddaraju N, Sridhar E, Soundararaghavan J, Habeebullah S: Unusual ovarian malignancies in ascitic fluid: a report of 2 cases. Acta Cytol; 2010 Jul-Aug;54(4):611-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Ovarian tumors of germ cell and sex-cord stromal derivation rarely exfoliate malignant cells in serous effusions.
  • A precise tissue diagnosis in these cases may be possible on serous body fluid cytology with a combined clinical and cytopathologic approach.
  • Following histopathologic diagnosis, cytologic materials were reviewed, which revealed certain features such as hyaline globules in YST and distinct tubular structures in JGCT.
  • These cytologic findings in view of the younger age of the patients should have prompted the correct diagnosis.
  • This simple and systematic approach is of great practical value in identifying certain cytomorphologic features that may aid in correct diagnosis.
  • [MeSH-major] Ascites / pathology. Endodermal Sinus Tumor / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20715666.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


49. Baykal C, Arioğlu P, Gultekin M, Usubutun A, Ficicioglu C, Ayhan A: Well differentiated mesothelioma complicating endometrial carcinoma; a case report. Eur J Gynaecol Oncol; 2006;27(2):200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peritoneal mesothelioma is a rare cancer of the abdominal cavity which has low malignant potential.
  • Peritoneal mesothelioma can mimic other types of gynecologic malignancies.
  • Careful clinical and pathologic evaluation is essential for an accurate diagnosis and treatment.
  • [MeSH-major] Adenocarcinoma / diagnosis. Endometrial Neoplasms / complications. Endometrial Neoplasms / diagnosis. Mesothelioma / diagnosis. Mesothelioma / etiology. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Ascites / etiology. Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620073.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


50. Shitara K, Munakata M, Kasai M, Muto O, Sakata Y: Prolongation of survival and improvement in performance status following palliative chemotherapy in gastrointestinal cancer patients with a poor performance status. Oncology; 2008;74(3-4):135-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 65 patients with ascites and/or pleural effusion, 12 patients achieved decreased fluid accumulation.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Karnofsky Performance Status / statistics & numerical data. Male. Middle Aged. Pleural Effusion, Malignant / pathology. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18714163.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


51. Tuzun Y, Yilmaz S, Dursun M, Canoruc F, Celik Y, Cil T, Boyraz T: How to increase the diagnostic value of malignancy-related ascites: discriminative ability of the ascitic tumour markers. J Int Med Res; 2009 Jan-Feb;37(1):87-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How to increase the diagnostic value of malignancy-related ascites: discriminative ability of the ascitic tumour markers.
  • Making a differential diagnosis between malignant and non-malignant ascites is an important clinical issue, but cytological examination has a relatively low diagnostic sensitivity.
  • This study aimed to find a discriminative model that distinguished between malignancy-related and non-malignant ascites.
  • The study included 107 patients: 50 with non-malignant and 57 with malignant ascites.
  • Ascites was analysed using a range of tumour markers and standard cytology.
  • Standardized canonical discriminant function coefficients were used to distinguish between ascites types.
  • The combination of carbohydrate antigen (CA) 15-3, carcinoembryonic antigen (CEA) and cytokeratin 19 fragments (CYFRA-21.1) discriminated between malignancy-related ascites and non-malignant ascites with an accuracy of 98.8% compared with an accuracy of 77.8% for cytological examination.
  • In conclusion, the use of a discriminant function constructed from a combination of CA15-3, CEA and CYFRA-21.1 could distinguish malignant from non-malignant ascites with greater accuracy than cytological examination.
  • [MeSH-major] Ascites / complications. Ascites / metabolism. Biomarkers, Tumor / analysis. Neoplasms / complications. Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215677.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


52. Tafur AJ, Quevedo F: Do we see spontaneous bacterial peritonitis in patients with malignant ascites? Acta Gastroenterol Latinoam; 2005;35(3):196-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do we see spontaneous bacterial peritonitis in patients with malignant ascites?
  • [MeSH-major] Ascites / microbiology. Bacterial Infections / microbiology. Neoplasms / microbiology. Peritonitis / microbiology
  • [MeSH-minor] Humans. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / microbiology

  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16333978.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Argentina
  •  go-up   go-down


53. Gupta S, Maheshwari A, Wuntkal R, Mazid T, Tongaonkar HB: Diagnostic dilemma in an elderly woman with intractable ascites and elevated CA-125 level. J Assoc Physicians India; 2006 Aug;54:655-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic dilemma in an elderly woman with intractable ascites and elevated CA-125 level.
  • In patients with intractable ascites, careful consideration should be given to the patient's past history with emphasis on cardiac, liver and renal disorders.
  • Ascitic fluid cytology indicating the presence of malignant cells should be unequivocal; cytology should be repeated before embarking on potentially toxic anti-cancer treatment in ambiguous cases.
  • Elevated serum CA-125 levels should not be relied upon to make the diagnosis of ovarian/peritoneal carcinoma.
  • We report a case of tricuspid stenosis with severe ascites in an elderly woman who was initially mis-diagnosed and treated as peritoneal/ovarian carcinoma.
  • [MeSH-major] Ascites / diagnosis. CA-125 Antigen / blood. Tricuspid Valve Stenosis / diagnosis
  • [MeSH-minor] Catheterization. Diagnostic Errors. Female. Heart Valve Prosthesis. Humans. Middle Aged. Ovarian Neoplasms. Peritoneal Neoplasms / diagnosis. Prosthesis Failure

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16941798.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


54. Matei D, Kelich S, Cao L, Menning N, Emerson RE, Rao J, Jeng MH, Sledge GW: PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biol Ther; 2007 Dec;6(12):1951-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • VEGF secretion in ovarian tumors, cancer cells, serum and ascites fluid was measured by IHC, Western Blot and ELISA.
  • We found increased VEGF expression and secretion in most ovarian tumors (by IHC), in EOC malignant ascites and in the conditioned media of primary ovarian cancer cells (quantified by ELISA).
  • In malignant ascites, the levels of secreted PDGF BB and VEGF were strongly correlated (Pearson coefficient of correlation R = 0.728), suggesting that the two pathways interconnect.
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Ascitic Fluid / chemistry. Benzamides. Cell Line, Tumor / secretion. Female. Humans. Imatinib Mesylate. Ovary / secretion. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / secretion. Phosphatidylinositol 3-Kinases / physiology. Piperazines / pharmacology. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins c-akt / physiology. Proto-Oncogene Proteins c-sis. Pyrimidines / pharmacology. Receptor, Platelet-Derived Growth Factor alpha / analysis. Receptor, Platelet-Derived Growth Factor beta / physiology. Recombinant Fusion Proteins / physiology. Signal Transduction / physiology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18075302.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Neoplasm Proteins; 0 / Piperazines; 0 / Platelet-Derived Growth Factor; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins c-sis; 0 / Pyrimidines; 0 / Recombinant Fusion Proteins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / platelet-derived growth factor A; 0 / platelet-derived growth factor BB; 8A1O1M485B / Imatinib Mesylate; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


55. Dillehay GL, Ellerbroek NA, Balon H, Brill DR, Grigsby PW, Macklis RM, Mauch PM, Mian TA, Potters L, Silberstein EB, Williams TR, Wong JC, Gaspar LE, American Society for Therapeutic Radiology and Oncology: Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources. Int J Radiat Oncol Biol Phys; 2006 Apr 1;64(5):1299-307
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Ascites / radiotherapy. Bone Neoplasms / radiotherapy. Bone Neoplasms / secondary. Chromium Compounds / therapeutic use. Humans. Hyperthyroidism / radiotherapy. Iodine Radioisotopes / therapeutic use. Lymphoma, Non-Hodgkin / radiotherapy. Organometallic Compounds / therapeutic use. Organophosphorus Compounds / therapeutic use. Pain / etiology. Pain / radiotherapy. Patient Isolation / standards. Phosphates / therapeutic use. Pleural Effusion, Malignant / radiotherapy. Polycythemia Vera / radiotherapy. Radiation Protection / standards. Sodium Iodide / therapeutic use. Strontium Radioisotopes / therapeutic use. Thrombocytopenia / radiotherapy. Thyroid Neoplasms / radiotherapy. Yttrium Radioisotopes / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHROMIUM COMPOUNDS .
  • Hazardous Substances Data Bank. SODIUM IODIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16472933.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Chromium Compounds; 0 / Iodine Radioisotopes; 0 / Organometallic Compounds; 0 / Organophosphorus Compounds; 0 / Phosphates; 0 / Radiopharmaceuticals; 0 / Strontium Radioisotopes; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan; 0 / iodine-131 anti-B1 antibody; 122575-21-7 / samarium ethylenediaminetetramethylenephosphonate; 7789-04-0 / chromic phosphate; F5WR8N145C / Sodium Iodide; SE337SVY37 / sodium phosphate
  •  go-up   go-down


56. Kim KW, Choi HJ, Kang S, Park SY, Jung DC, Cho JY, Cho KS, Kim SH: The utility of multi-detector computed tomography in the diagnosis of malignant pleural effusion in the patients with ovarian cancer. Eur J Radiol; 2010 Aug;75(2):230-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of multi-detector computed tomography in the diagnosis of malignant pleural effusion in the patients with ovarian cancer.
  • PURPOSE: The purpose of this study was to retrospectively assess possible clinical predictors of malignant pleural effusion in patients with ovarian cancer.
  • MATERIALS AND METHODS: This review was performed on 38 ovarian cancer patients that showed pleural effusion in a CT scan and who underwent thoracocentesis before treatment.
  • Fisher's exact test was used to determine the probability of malignant pleural effusion as a function of; amount of ascites, lymph node enlargement, amount of pleural effusion, pleural nodules, and pleural thickening.
  • RESULTS: Sixteen (42.1%) of the 38 patients had malignant pleural effusion and malignant pleural effusion amounts were greater than those with nonmalignant effusion.
  • Pleural nodules were more frequently found in the malignant pleural effusion group (eight [50%] patients) than in the nonmalignant group (zero [0%] patient) (p<0.001).
  • Supradiaphragmatic lymph node enlargement (with short axis diameter 1cm or more) was more frequent in malignant group (12 [75%] patients) than in the nonmalignant group (two [9.1%] patients) (p<0.001).
  • CONCLUSION: The probability of malignant pleural effusion in patients with ovarian cancer was found to be correlated with the amount of pleural effusion, the presence of pleural nodules, and supradiaphragmatic lymph node enlargement.
  • [MeSH-major] Ovarian Neoplasms / complications. Pleural Effusion, Malignant / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19481402.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


57. Novellas S, Denys A, Bize P, Brunner P, Motamedi JP, Gugenheim J, Caroli FX, Chevallier P: Palliative portal vein stent placement in malignant and symptomatic extrinsic portal vein stenosis or occlusion. Cardiovasc Intervent Radiol; 2009 May;32(3):462-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative portal vein stent placement in malignant and symptomatic extrinsic portal vein stenosis or occlusion.
  • This article evaluates the results of portal vein (PV) stent placement in patients with malignant extrinsic lesions stenosing or obstructing the PV and causing symptomatic PV hypertension (PVHT).
  • Fourteen patients with bile duct cancer (n = 7), pancreatic adenocarcinoma (n = 4), or another cancer (n = 3) underwent percutaneous transhepatic portal venous stent placement because of gastroesophageal or jejunal varices (n = 9), ascites (n = 7), and/or thrombocytopenia (n = 2).

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18956224.001).
  • [ISSN] 1432-086X
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Chelius D, Ruf P, Gruber P, Plöscher M, Liedtke R, Gansberger E, Hess J, Wasiliu M, Lindhofer H: Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs; 2010 May-Jun;2(3):309-19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Catumaxomab (Removab) was launched in Europe for treatment of malignant ascites in April 2009.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Chem Soc. 1965 Jan 20;87:218-28 [14228459.001]
  • [Cites] J Chromatogr A. 2004 Oct 22;1053(1-2):299-305 [15543996.001]
  • [Cites] Anal Chem. 2005 Sep 15;77(18):6004-11 [16159134.001]
  • [Cites] J Chromatogr A. 2006 Jan 13;1102(1-2):164-75 [16297926.001]
  • [Cites] Carbohydr Res. 2006 Feb 27;341(3):410-9 [16378604.001]
  • [Cites] Anal Chem. 2006 Apr 1;78(7):2370-6 [16579622.001]
  • [Cites] J Chromatogr A. 2006 Jul 7;1120(1-2):112-20 [16448656.001]
  • [Cites] Science. 2006 Aug 4;313(5787):670-3 [16888140.001]
  • [Cites] J Pharm Sci. 2007 Feb;96(2):268-79 [17080424.001]
  • [Cites] Biochemistry. 2007 Feb 13;46(6):1534-44 [17279618.001]
  • [Cites] Nat Protoc. 2006;1(6):2876-90 [17406547.001]
  • [Cites] Pharm Res. 2007 Jun;24(6):1145-56 [17385019.001]
  • [Cites] Anal Biochem. 2007 Aug 15;367(2):225-37 [17548043.001]
  • [Cites] Br J Cancer. 2007 Aug 6;97(3):315-21 [17622246.001]
  • [Cites] Expert Opin Biol Ther. 2007 Sep;7(9):1401-13 [17727329.001]
  • [Cites] J Chromatogr A. 2007 Dec 14;1175(1):63-8 [17980377.001]
  • [Cites] Biol Chem. 2008 Jan;389(1):37-45 [18095868.001]
  • [Cites] J Chromatogr A. 2008 Feb 1;1179(2):198-204 [18096172.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1504-11 [17993615.001]
  • [Cites] Biochemistry. 2008 Feb 26;47(8):2518-30 [18232715.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4081-2 [18344326.001]
  • [Cites] Biochemistry. 2008 May 6;47(18):5088-100 [18407665.001]
  • [Cites] J Biol Chem. 2008 Jun 6;283(23):16194-205 [18339624.001]
  • [Cites] J Biol Chem. 2008 Jun 6;283(23):16206-15 [18339626.001]
  • [Cites] Curr Opin Mol Ther. 2008 Jun;10(3):273-84 [18535935.001]
  • [Cites] Biotechnol Bioeng. 2008 Aug 15;100(6):1132-43 [18553400.001]
  • [Cites] Int J Cancer. 2008 Sep 1;123(5):1181-9 [18546289.001]
  • [Cites] J Am Soc Mass Spectrom. 2008 Nov;19(11):1643-54 [18707900.001]
  • [Cites] Rapid Commun Mass Spectrom. 2008 Dec;22(24):4081-8 [19021137.001]
  • [Cites] Curr Pharm Biotechnol. 2008 Dec;9(6):468-81 [19075686.001]
  • [Cites] Protein Sci. 2009 Feb;18(2):424-33 [19165723.001]
  • [Cites] Mass Spectrom Rev. 2009 Mar-Apr;28(2):273-361 [18825656.001]
  • [Cites] Anal Chem. 2009 May 15;81(10):3933-43 [19358553.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4270-6 [19435924.001]
  • [Cites] Anal Biochem. 2009 Sep 15;392(2):145-54 [19497295.001]
  • [Cites] J Am Soc Mass Spectrom. 2009 Aug;20(8):1415-24 [19409810.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 15;877(30):3841-9 [19819766.001]
  • [Cites] Drugs Today (Barc). 2009 Aug;45(8):589-97 [19927225.001]
  • [Cites] MAbs. 2009 Nov-Dec;1(6):539-47 [20073127.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Mar 15;878(9-10):777-84 [20153988.001]
  • [Cites] Anal Chem. 2009 Aug 1;81(15):6148-55 [19591437.001]
  • [Cites] Biophys J. 2000 Mar;78(3):1606-19 [10692345.001]
  • [Cites] Nat Med. 2000 Apr;6(4):443-6 [10742152.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):261-6 [10901380.001]
  • [Cites] Pharm Res. 2000 Sep;17(9):1110-7 [11087044.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6591-604 [11096108.001]
  • [Cites] J Chromatogr B Biomed Sci Appl. 2001 Mar 10;752(2):233-45 [11270864.001]
  • [Cites] Biophys J. 2001 May;80(5):2093-109 [11325713.001]
  • [Cites] J Histochem Cytochem. 2001 Jul;49(7):911-7 [11410615.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1155-9 [11498595.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2526-34 [11588051.001]
  • [Cites] Anal Chem. 2001 Oct 15;73(20):4755-62 [11681448.001]
  • [Cites] J Pharm Biomed Anal. 2003 Jan 1;30(5):1479-90 [12467919.001]
  • [Cites] Anal Biochem. 2003 Oct 15;321(2):183-7 [14511682.001]
  • [Cites] Methods Enzymol. 2004;383:318-51 [15063656.001]
  • [Cites] Biochemistry. 1969 Oct;8(10):4108-16 [5346390.001]
  • [Cites] Anal Biochem. 1987 Jun;163(2):489-99 [3661998.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 May;85(10):3289-93 [3368440.001]
  • [Cites] J Chromatogr. 1989 Jan 6;461:73-87 [2708482.001]
  • [Cites] J Chromatogr. 1989 Feb 3;463(2):375-96 [2496137.001]
  • [Cites] J Biol Chem. 1989 Sep 25;264(27):15905-11 [2777770.001]
  • [Cites] Science. 1989 Oct 6;246(4926):64-71 [2675315.001]
  • [Cites] Methods Biochem Anal. 1990;34:145-201 [2181246.001]
  • [Cites] Methods Biochem Anal. 1991;35:127-205 [2002770.001]
  • [Cites] Anal Chem. 1991 Dec 15;63(24):2909-15 [1789452.001]
  • [Cites] Protein Eng. 1992 Apr;5(3):191-5 [1409538.001]
  • [Cites] Protein Sci. 1993 Sep;2(9):1520-31 [8401236.001]
  • [Cites] Anal Biochem. 1993 Oct;214(1):17-24 [8250221.001]
  • [Cites] Anal Chem. 1994 Jan 1;66(1):126-33 [8116874.001]
  • [Cites] Q J Nucl Med. 1995 Jun;39(2):129-33 [8574807.001]
  • [Cites] Anal Biochem. 1996 Jul 15;239(1):92-8 [8660630.001]
  • [Cites] Anal Biochem. 1996 Jan 15;233(2):234-42 [8789724.001]
  • [Cites] Anal Biochem. 1996 Sep 5;240(2):210-26 [8811911.001]
  • [Cites] J Pharm Sci. 1997 Nov;86(11):1250-5 [9383735.001]
  • [Cites] Glycobiology. 1998 May;8(5):445-54 [9597542.001]
  • [Cites] J Immunol. 1999 Aug 1;163(3):1246-52 [10415020.001]
  • (PMID = 20418662.001).
  • [ISSN] 1942-0870
  • [Journal-full-title] mAbs
  • [ISO-abbreviation] MAbs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Light Chains; 0 / catumaxomab
  • [Other-IDs] NLM/ PMC2881257
  •  go-up   go-down


59. Hagiwara Y, Hamada Y, Kuwahara M, Maeda M, Segawa T, Ishikawa K, Hino O: Establishment of a novel specific ELISA system for rat N- and C-ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesothelioma. Cancer Sci; 2008 Apr;99(4):666-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesothelioma is a type of malignant tumor that most commonly arises from the pleural or peritoneal membrane and is usually associated with previous exposure to asbestos.
  • In this study, we consider the development of a novel specific ELISA system for not only rat N-ERC/mesothelin but also C-ERC/mesothelin, and the first data on the presence of rat ERC/mesothelin in the body fluids of rat malignant mesothelioma-bearing nude mice.
  • The transplanted mice have revealed the higher concentrations of rat N-ERC/mesothelin in the blood and ascites than C-ERC/mesothelin.
  • [MeSH-major] Body Fluids / chemistry. Enzyme-Linked Immunosorbent Assay / methods. Membrane Glycoproteins / analysis. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. ASBESTOS .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294289.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 1332-21-4 / Asbestos
  •  go-up   go-down


60. Shen J, Zhu Z: Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer. Curr Opin Mol Ther; 2008 Jun;10(3):273-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fresenius Biotech GmbH (licensed from TRION Pharma GmbH) is developing catumaxomab, a rat/murine hybrid, trifunctional, bispecific (anti-epithelial cell adhesion molecule and anti-CD3) mAb for the potential intravenous and intraperitoneal treatment of ovarian cancer, gastric cancer, malignant pleural effusion and other cancers, and also for malignant ascites associated with various cancers.
  • In 2007, following the successful completion of a phase II/III clinical trial in patients with malignant ascites from various cancers, Fresenius filed for European approval.
  • Catumaxomab is currently undergoing phase II clinical trials in patients with malignant ascites, ovarian and stomach cancer.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18535935.001).
  • [ISSN] 1464-8431
  • [Journal-full-title] Current opinion in molecular therapeutics
  • [ISO-abbreviation] Curr. Opin. Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antibodies, Monoclonal; 0 / catumaxomab
  •  go-up   go-down


61. Huang YD, Hung YC, Yeh LS, Chiang IP, Zeng GC, Chang WC: Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma. Taiwan J Obstet Gynecol; 2006 Sep;45(3):264-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography showed an 18 x 16 cm right pelvic tumor, with both cystic and solid components, ascites and bilateral massive pleural effusion.
  • Cytology of the pleural effusion showed no malignant cells.
  • Diagnosis should be based on histologic examination and requires appropriate treatment for both tumors.


62. Sebastian M, Kuemmel A, Schmidt M, Schmittel A: Catumaxomab: a bispecific trifunctional antibody. Drugs Today (Barc); 2009 Aug;45(8):589-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Catumaxomab has been approved in Europe for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive epithelial tumors when standard therapy is not available or is no longer feasible.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.
  • (PMID = 19927225.001).
  • [ISSN] 1699-3993
  • [Journal-full-title] Drugs of today (Barcelona, Spain : 1998)
  • [ISO-abbreviation] Drugs Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / catumaxomab
  • [Number-of-references] 42
  •  go-up   go-down


63. Presneau N, Shen Z, Provencher D, Mes-Masson AM, Tonin PN: Identification of novel variant, 1484delG in the 3'UTR of H3F3B, a member of the histone 3B replacement family, in ovarian tumors. Int J Oncol; 2005 Jun;26(6):1621-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OV90 was derived from ascites fluid of an undifferentiated adenocarcinoma of ovarian origin.
  • The variant allele was identified in 1 of 65 (2%) healthy women with no prior history of cancer and in 5 participants with ovarian tumors comprising of 4 of 79 (5%) malignant EOC, none of 10 low malignancy potential tumors, and 1 of 8 (13%) benign tumors.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870878.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / Histones
  •  go-up   go-down


64. Fleming ND, Alvarez-Secord A, Von Gruenigen V, Miller MJ, Abernethy AP: Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. J Pain Symptom Manage; 2009 Sep;38(3):341-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review.
  • The safety and efficacy of indwelling intraperitoneal (IP) catheters for the management of refractory malignant ascites is unclear.
  • A systematic literature overview and retrospective chart review of patients with malignant refractory ascites who underwent indwelling IP catheter placement was performed.
  • Tenckhoff (Quinton Instrument Company, Seattle, WA, USA), Pleurex (Denver Biomedical Inc., Golden, CO, USA), and peritoneal catheters were used, along with IP ports.
  • Median time from diagnosis to catheter placement was 25 months (range: 1-77).
  • In these retrospective studies, indwelling IP catheters appear to be a safe and effective palliative strategy to manage refractory malignant ascites, without overwhelming infection rates.
  • [MeSH-major] Ascites / therapy. Catheters, Indwelling

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19328648.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


65. Mizrahi A, Czerniak A, Ohana P, Amiur S, Gallula J, Matouk I, Abu-Lail R, Birman T, Hochberg A, Levy T: Treatment of ovarian cancer ascites by intra-peritoneal injection of diphtheria toxin A chain-H19 vector: a case report. J Med Case Rep; 2010;4:228
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of ovarian cancer ascites by intra-peritoneal injection of diphtheria toxin A chain-H19 vector: a case report.
  • INTRODUCTION: Ovarian cancer ascitic fluid, which contains malignant cells, is usually present in women with an advanced stage disease.
  • She suffered from progressive disease, accumulation of malignant ascites that needed to be drained weekly, abdominal pain, vomiting, anorexia and severe weakness.
  • Infusion of the diphtheria toxin A chain-H19 plasmid into the peritoneum of our patient resulted in complete resolution of the ascites with minimum adverse events.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Biochem. 1992;61:331-54 [1497314.001]
  • [Cites] Cell. 1987 Jul 31;50(3):435-43 [3649277.001]
  • [Cites] Science. 1987 Dec 11;238(4833):1563-5 [3685993.001]
  • [Cites] Hum Gene Ther. 1995 Feb;6(2):137-43 [7734514.001]
  • [Cites] Urology. 1995 Feb;45(2):335-8 [7855987.001]
  • [Cites] J Transl Med. 2009;7:69 [19656414.001]
  • [Cites] J Surg Oncol. 1999 Mar;70(3):145-9 [10102343.001]
  • [Cites] Nucleic Acids Res. 2001 Jan 1;29(1):189-93 [11125087.001]
  • [Cites] Lancet Oncol. 2003 May;4(5):277-83 [12732164.001]
  • [Cites] Cancer Treat Res. 2007;134:131-52 [17633051.001]
  • [Cites] PLoS One. 2007;2(9):e845 [17786216.001]
  • [Cites] Mol Pathol. 1998 Feb;51(1):21-5 [9624415.001]
  • (PMID = 20663201.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2918631
  •  go-up   go-down


66. Badmus TA, Adesunkanmi AR, Agbakwuru CA, Salako AA, Uhunmwagho O, Eziyi AK: Giant renal oncocytoma masquerading as infiltrating renal cell carcinoma: case report and literature review. Cent Afr J Med; 2006 Jan-Feb;52(1-2):16-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There was no tumour extension to the renal vein, no peritoneal seedling, no nodal metastasis and no ascites.
  • This presentation, besides highlighting the possible giant nature of RO, also illustrates the malignant potential of RO to infiltrate contiguous structures and mimics infiltrating RCC.
  • In view of the difficulties at establishing pre-operative diagnosis in this disease and because nephron-sparing surgery is curative, especially for the well-circumscribed tumours, RO should be considered in the management of patients with features of infiltrating RCC.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Kidney Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Renal Cell / diagnosis. Diagnosis, Differential. Female. Humans. Middle Aged


67. Gong HL, Wang CB, Zhang GJ, Li CF, Yang XY, Hou HL, Zhang XB: [Clinicopathological analysis and differential diagnosis of primary peritoneal adenocarcinoma]. Zhonghua Yi Xue Za Zhi; 2009 Feb 24;89(7):463-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological analysis and differential diagnosis of primary peritoneal adenocarcinoma].
  • OBJECTIVE: To investigate the clinicopathological characteristics and differential diagnosis of primary peritoneal adenocarcinoma.
  • METHODS: The clinico-pathological data of 8 patients with primary peritoneal adenocarcinoma, all female, aged 55.7 (45 - 69), were analyzed retrospectively.
  • RESULTS: The common clinical symptoms of these 8 patients included abdominal distention and ascites.
  • Pre-operationally, 6 cases were diagnosed as with ovarian cancer, I case as with malignant mesothelioma, and I as with peritoneal carcinoma.
  • CONCLUSION: A rare malignant tumor arising from the secondary Müllerian system, primary peritoneal adenocarcinoma shares similar histopathological characters with ovary carcinoma, so is easy to be misdiagnosed.
  • Immunohistochemical staining is helpful to the differential diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19567094.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


68. Huang SE, Huang SC, Lee WY, Hsu KF: Pseudo-Meigs' syndrome caused by uterine smooth muscle tumor of uncertain malignant potential with low vascular endothelial growth factor expression. Int J Gynecol Cancer; 2008 Jul-Aug;18(4):851-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudo-Meigs' syndrome caused by uterine smooth muscle tumor of uncertain malignant potential with low vascular endothelial growth factor expression.
  • Smooth muscle tumor of uncertain malignant potential (STUMP) presenting as pseudo-Meigs' syndrome with low vascular endothelial growth factor (VEGF) expression has not been reported in previous literature.
  • Here, we report a case of uterine STUMP associated with ascites and pleural effusion, which was resolved completely after hysterectomy.
  • Sonography and computed tomography showed a hypervascular solid pelvic mass measuring 20 x 17 x 15 cm in size associated with ascites and right pleural effusion.
  • Laparotomy revealed a large uterine mass with ascites in the abdomen.
  • A follow-up chest X-ray revealed that the pleural effusion was resolved completely 1 week postoperatively.
  • However, the ascites or the pleural effusion may not be induced by VEGF, known as vascular permeability factor, in our case.
  • [MeSH-minor] Disease Progression. Down-Regulation. Female. Humans. Middle Aged. Pleural Effusion, Malignant / radiography

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17944915.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


69. Wang GP, Guan YS, Jin XR, Jiang SS, Lu ZJ, Wu Y, Li Y, Li M, Luo F: Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites. J Gastroenterol Hepatol; 2010 May;25(5):985-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites.
  • BACKGROUND: To investigate pharmacokinetics and potency of antitumor activity of a novel 5-fluorouracil carrier erythrocyte (RBC-FU) in mice bearing malignant ascites.
  • After a H22 hepatocarcinoma malignant ascites model was established in Kunming mice, 5-FU encapsulated by carrier erythrocytes (for Group A) and 5-FU solution (for Group B) at 20 mg per kg were injected into the peritoneal cavity of the mice, respectively.
  • Blood and ascites samples were collected at different times to detect 5-FU quantity by HPLC.
  • In Group A, the maximum concentration (Cmax) and the area under curve (AUC) in peritoneal exudates were significantly higher than those of Group B (P < 0.05).
  • On the other hand, 5-FU level in serum was significantly lower than that in peritoneal exudates of Group A and B (P < 0.05).
  • Compared with that in Group B and the control, the quantity of malignant ascites in Group A had significant regression and the survival time was prolonged.
  • CONCLUSION: The hyperosmotic method described here could be suitable for producing this novel RBC-FU as a liposomal drug of potential value for treating malignant ascites by intraperitoneal administration.
  • [MeSH-major] Antimetabolites, Antineoplastic / blood. Antimetabolites, Antineoplastic / pharmacology. Drug Carriers. Erythrocyte Transfusion. Erythrocytes / metabolism. Fluorouracil / blood. Fluorouracil / pharmacology. Liver Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20546454.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Carriers; 0 / Liposomes; U3P01618RT / Fluorouracil
  •  go-up   go-down


70. Zheng R, Yano S, Zhang H, Nakataki E, Tachibana I, Kawase I, Hayashi S, Sone S: CD9 overexpression suppressed the liver metastasis and malignant ascites via inhibition of proliferation and motility of small-cell lung cancer cells in NK cell-depleted SCID mice. Oncol Res; 2005;15(7-8):365-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD9 overexpression suppressed the liver metastasis and malignant ascites via inhibition of proliferation and motility of small-cell lung cancer cells in NK cell-depleted SCID mice.
  • Parental and mock-transfected OS3-R5 cells developed liver metastasis and malignant ascites when they were intravenously inoculated into NK cell-depleted SCID mice.
  • CD9 gene transfection into OS3-R5 cells caused suppression of the liver metastasis and malignant ascites.
  • [MeSH-major] Antigens, CD / biosynthesis. Ascites / pathology. Carcinoma, Small Cell / secondary. Liver Neoplasms / secondary. Lung Neoplasms / pathology. Membrane Glycoproteins / biosynthesis


71. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B, Nye E, Stamp G, Alitalo K, Downward J: Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell; 2007 Jun 1;129(5):957-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the ability of Ras to control PI 3-kinase has been well established in manipulated cell culture models, evidence for a role of the interaction of endogenous Ras with PI 3-kinase in normal and malignant cell growth in vivo has been lacking.
  • The mice display defective development of the lymphatic vasculature, resulting in perinatal appearance of chylous ascites.


72. Ajith TA, Anu V, Riji T: Antitumor and apoptosis promoting properties of atorvastatin, an inhibitor of HMG-CoA reductase, against Dalton's Lymphoma Ascites tumor in mice. J Exp Ther Oncol; 2008;7(4):291-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor and apoptosis promoting properties of atorvastatin, an inhibitor of HMG-CoA reductase, against Dalton's Lymphoma Ascites tumor in mice.
  • Increased level of products of lipid peroxidation and cholesterol-enriched lipid domains in the plasma membrane can favorthe malignant transformation of cells.
  • An effective chemopreventive agent with hypolipaedemic effect will be worthwhile to intervene early in the process of carcinogenesis to eliminate the pre-malignant cells.
  • The antitumor activity was evaluated using Daltons' Lymphoma Ascites (DLA) cell line transplanted ascites tumor model in mice.
  • Proapoptotic activity was evaluated in DLA cell line induced ascites animals after the treatment of atorvastatin (4 and 16 mg/kg, i.p).
  • Atorvastatin significantly (P < 0.01) inhibited the ascites tumor growth at 16 mg/kg body wt (i.p).
  • Single dose of atorvastatin (16 mg/kg body wt) was also effective to promote the apoptosis of DLA cells in the ascites tumor bearing mice that was evident from the multiple fragmentation of DNA in agarose gel electrophoresis.
  • Further the morphological analysis of DLA cells aspirated from the atorvastatin treated ascites tumor bearing animals showed 36.34 +/- 6.78% apoptotic cells compared to the control animals (10.50 +/- 3.53%).

  • MedlinePlus Health Information. consumer health - Statins.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227009.001).
  • [ISSN] 1359-4117
  • [Journal-full-title] Journal of experimental therapeutics & oncology
  • [ISO-abbreviation] J. Exp. Ther. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents; 0 / Heptanoic Acids; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Pyrroles; 0 / Reactive Oxygen Species; 48A5M73Z4Q / Atorvastatin Calcium
  •  go-up   go-down


73. Ding S, Li C, Lin S, Yang Y, Liu D, Han Y, Zhang Y, Li L, Zhou L, Kumar S: Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. Hum Pathol; 2006 Jul;37(7):861-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions.
  • Correlation analysis showed that MVD determined by CD105 correlated with blood vessel invasion, distant metastasis, and formation of ascites.
  • Microvessel density determined by CD34 inversely correlated with overall survival, but it did not correlate with other clinicopathologic parameters except formation of ascites.
  • In conclusion, CD34 was universally expressed in blood vessels within benign and malignant tissues, whereas CD105 expression was minimal in benign tissues but stronger in gastric carcinoma.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784986.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Receptors, Cell Surface
  •  go-up   go-down


74. Maruno M, Ghulam Muhammad AK, Taguchi J, Suzuki T, Wada K, Isaka T, Yoshimine T: Giant cell type of primary intracranial malignant fibrous histiocytoma: a case report. Brain Tumor Pathol; 2006 Apr;23(1):65-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell type of primary intracranial malignant fibrous histiocytoma: a case report.
  • The primary intracranial giant cell type of malignant fibrous histiocytoma (GC-MFH) is rare, and the resemblance to meningioma causes diagnostic confusion.
  • We report one such case in which an extracranial malignant neoplasm was seen after the initial diagnosis and treatment.
  • The histopathological features were consistent with the diagnosis of GC-MFH.
  • Subsequently, she developed ascites and died 3 months later as a consequence of end-stage adenocarcinoma (ovary) with peritoneal dissemination.
  • [MeSH-major] Brain Neoplasms / pathology. Histiocytoma, Malignant Fibrous / pathology

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. HEMATOXYLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095121.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Coloring Agents; TDQ283MPCW / Eosine Yellowish-(YS); YKM8PY2Z55 / Hematoxylin
  •  go-up   go-down


75. Hays JL, Kim G, Giuroiu I, Kohn EC: Proteomics and ovarian cancer: integrating proteomics information into clinical care. J Proteomics; 2010 Sep 10;73(10):1864-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The power of proteomics allows unparalleled opportunity to query the molecular mechanisms of a malignant cell and the tumor microenvironment in patients with ovarian cancer and other solid tumors.
  • Proteomics analysis of serum and ascites has also given us sources with which to discover possible early markers for the presence of new disease and for the progression of established cancer throughout the course of treatment.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Proteomics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):1122-9 [17005245.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92 [17161157.001]
  • [Cites] Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9 [17218844.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(4):690-709 [17223544.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1323-30 [17330838.001]
  • [Cites] Clin Med Res. 2007 Mar;5(1):35-44 [17456833.001]
  • [Cites] Clin Chem. 2007 Jun;53(6):1067-74 [17463175.001]
  • [Cites] Rinsho Byori. 2007 May;55(5):417-27 [17593686.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):309-17 [17559139.001]
  • [Cites] J Clin Oncol. 2007 Jul 10;25(20):2902-8 [17617521.001]
  • [Cites] J Proteome Res. 2007 Sep;6(9):3558-65 [17696519.001]
  • [Cites] Am J Epidemiol. 2007 Oct 15;166(8):894-901 [17656616.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2321-30 [18006921.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5165-71 [18024863.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5180-6 [18024865.001]
  • [Cites] Proteomics. 2007 Nov;7(22):4045-52 [17952875.001]
  • [Cites] Proteomics. 2007 Nov;7(22):4090-101 [17994630.001]
  • [Cites] J Clin Oncol. 2008 Jan 1;26(1):76-82 [18165643.001]
  • [Cites] J Proteome Res. 2008 Jan;7(1):339-51 [18076136.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):402-8 [18061248.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1065-72 [18258665.001]
  • [Cites] Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:1-6 [18336391.001]
  • [Cites] Mol Biosyst. 2008 Jul;4(7):762-73 [18563251.001]
  • [Cites] Gynecol Oncol. 2008 Jul;110(1):49-55 [18423560.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Acta Pharmacol Sin. 2008 Oct;29(10):1240-6 [18817630.001]
  • [Cites] Gynecol Oncol. 2008 Oct;111(1):111-9 [18703221.001]
  • [Cites] J Zhejiang Univ Sci B. 2008 Nov;9(11):863-70 [18988305.001]
  • [Cites] Clin Cancer Res. 2008 Nov 15;14(22):7574; author reply 7577-9 [18948386.001]
  • [Cites] Clin Cancer Res. 2008 Nov 15;14(22):7554-63 [19010874.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):40-6 [18851871.001]
  • [Cites] Biochim Biophys Acta. 2009 Feb;1794(2):225-36 [18973835.001]
  • [Cites] Acta Obstet Gynecol Scand. 2009;88(1):18-26 [19023702.001]
  • [Cites] Nat Rev Cancer. 2009 Mar;9(3):167-81 [19238149.001]
  • [Cites] Cell Prolif. 2009 Apr;42(2):219-28 [19222485.001]
  • [Cites] Mol Cell Proteomics. 2009 Apr;8(4):661-9 [19047685.001]
  • [Cites] Lancet Oncol. 2009 Apr;10(4):327-40 [19282241.001]
  • [Cites] Electrophoresis. 2009 Apr;30(7):1119-31 [19288585.001]
  • [Cites] Mol Diagn Ther. 2009;13(2):73-90 [19537843.001]
  • [Cites] N Engl J Med. 2009 Jul 9;361(2):123-34 [19553641.001]
  • [Cites] Gene. 1999 Oct 1;238(2):375-85 [10570965.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2068-75 [11066047.001]
  • [Cites] Cancer Treat Res. 2002;107:247-58 [11775453.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Nat Rev Drug Discov. 2002 Sep;1(9):683-95 [12209149.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):433-9 [12927430.001]
  • [Cites] Proteomics. 2009 Jul;9(13):3535-48 [19609961.001]
  • [Cites] OMICS. 2009 Aug;13(4):345-54 [19422301.001]
  • [Cites] Clin Cancer Res. 2009 Sep 1;15(17):5317-22 [19706816.001]
  • [Cites] Breast Cancer Res. 2009;11(4):R47 [19589159.001]
  • [Cites] Eur J Surg Oncol. 2010 Feb;36(2):201-7 [19674866.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3709-14 [18669456.001]
  • [Cites] Am J Obstet Gynecol. 2008 Sep;199(3):215-23 [18468571.001]
  • [Cites] Mol Cell Proteomics. 2003 Oct;2(10):1096-103 [12917320.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):355-66 [14764655.001]
  • [Cites] N Engl J Med. 1990 Apr 12;322(15):1021-7 [2181310.001]
  • [Cites] Am J Hum Genet. 1993 Apr;52(4):678-701 [8460634.001]
  • [Cites] Lancet. 1994 Mar 19;343(8899):692-5 [7907678.001]
  • [Cites] Science. 1994 Sep 30;265(5181):2088-90 [8091231.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):804-10 [9126738.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):255-64 [9633839.001]
  • [Cites] Am J Pharmacogenomics. 2005;5(3):141-8 [15952868.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):172-87 [16014887.001]
  • [Cites] Pharmacogenomics. 2005 Sep;6(6):647-53 [16143004.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):791-9 [16467090.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):988-94 [16461779.001]
  • [Cites] Proteomics. 2006 Oct;6(19):5183-92 [16941573.001]
  • (PMID = 20561909.001).
  • [ISSN] 1876-7737
  • [Journal-full-title] Journal of proteomics
  • [ISO-abbreviation] J Proteomics
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999; United States / Intramural NIH HHS / / ZIA SC009374-18; United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS220029; NLM/ PMC2939206
  •  go-up   go-down


76. Haga A: [Possibility that AMF will serve as a target molecule for the diagnosis and treatment of a metastatic neoplasm]. Yakugaku Zasshi; 2005 Feb;125(2):169-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Possibility that AMF will serve as a target molecule for the diagnosis and treatment of a metastatic neoplasm].
  • The AMF was thought to be an autocrine factor as the name shows it, and it is peculiar to malignant cells.
  • Especially, endothelial cells which are essential parts of tumor induced angiogenesis or ascites accumulation express the AMF-receptor and they responded to AMF stimulation.
  • Metastasis is a most complicated biological phenomenon that a large number of molecules or factors induced by tumor and host are related, thus AMF is also unusual molecule reacting between tumor and host tissues, and therefore AMF should be a target of treatment or diagnosis of cancer.
  • [MeSH-major] Glucose-6-Phosphate Isomerase. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / therapy

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15684571.001).
  • [ISSN] 0031-6903
  • [Journal-full-title] Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
  • [ISO-abbreviation] Yakugaku Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Receptors, Cytokine; EC 5.3.1.9 / Glucose-6-Phosphate Isomerase; EC 6.3.2.19 / AMFR protein, human; EC 6.3.2.19 / Receptors, Autocrine Motility Factor; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Number-of-references] 64
  •  go-up   go-down


77. Scholz C, Rampf E, Toth B, Brunnhuber R, Weissenbacher T, Friese K, Jeschke U: Ovarian cancer-derived glycodelin impairs in vitro dendritic cell maturation. J Immunother; 2009 Jun;32(5):492-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gd was isolated with high performance liquid chromatography from the malignant ascites of ovarian cancer patients.
  • Gd, which is found in the malignant ascites of ovarian cancer patients, induces a tolerogenic phenotype in DC, thereby shaping an immunodeficient tumor micromilieu.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19609241.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation; 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / Glycoproteins; 0 / ICAM3 protein, human; 0 / Immunosuppressive Agents; 0 / PAEP protein, human; 0 / Pregnancy Proteins; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 77238-31-4 / Interferon-beta
  •  go-up   go-down


78. Yonemori K, Okusaka T, Ueno H, Morizane C, Takesako Y, Ikeda M: FP therapy for controlling malignant ascites in advanced pancreatic cancer patients. Hepatogastroenterology; 2007 Dec;54(80):2383-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FP therapy for controlling malignant ascites in advanced pancreatic cancer patients.
  • BACKGROUND/AIMS: Malignant ascites is one of the poor prognostic factors for pancreatic cancer, and causes serious symptoms and treatment-related toxicity.
  • We conducted a retrospective analysis to evaluate the efficacy of 5-fluorouracil (5-FU) plus cisplatin (FP therapy) for controlling malignant ascites in patients with advanced pancreatic cancer.
  • METHODOLOGY: This analysis was based on 28 consecutive chemotherapy-naive advanced pancreatic cancer patients with cytologically proven malignant ascites who were treated with FP therapy from November 1991 to April 2003.
  • The objective improvement of ascites was seen in 35.7% of the patients (N = 10/28, 95% confidence interval, 18.0 to 53.4%), but there was no patient with complete disappearance of ascites.
  • In all pretreatment variables, the presence of distant metastasis other than peritoneal dissemination was an unfavorable predictive factor for the objective improvement of ascites (Fisher's exact test: P = 0.002).
  • CONCLUSIONS: FP therapy was modestly effective for controlling malignant ascites but insufficient in shrinking for measurable metastatic lesions.
  • Systemic chemotherapy for controlling malignant ascites might be worth while for palliative management in advanced pancreatic cancer patients, especially in patients without distant metastasis.
  • [MeSH-major] Adenocarcinoma / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / drug therapy. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Pancreatic Neoplasms / complications

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18265670.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 9007-41-4 / C-Reactive Protein; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


79. Won JY, Choi SY, Ko HK, Kim SH, Lee KH, Lee JT, Lee DY: Percutaneous peritoneovenous shunt for treatment of refractory ascites. J Vasc Interv Radiol; 2008 Dec;19(12):1717-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous peritoneovenous shunt for treatment of refractory ascites.
  • PURPOSE: To evaluate the usefulness of a percutaneously placed peritoneovenous shunt (PVS) in patients with refractory ascites.
  • MATERIALS AND METHODS: Under fluoroscopic and ultrasonographic (US) guidance, the authors placed a PVS in 55 patients (39 men and 16 women; mean age, 56 years) with refractory ascites and symptomatic abdominal distention.
  • The cause of ascites was liver cirrhosis (n = 36), carcinomatosis (n = 17), ruptured cysts with polycystic kidney disease (n = 1), and idiopathic refractory ascites (n = 1).
  • Complications occurred in 17 of the 55 patients (31%): five patients had variceal bleeding; three patients had ascites leakage; two patients each had disseminated intravascular coagulopathy, transient abdominal pain, shunt infection, and venous thrombosis; and one patient had pulmonary thromboembolism.
  • There was no significant difference in shunt patency between the two groups with benign and malignant ascites.
  • CONCLUSIONS: The percutaneous placement of a PVS was a technically feasible and effective method for symptomatic relief of refractory ascites.
  • [MeSH-major] Ascites / surgery. Peritoneovenous Shunt

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18948021.001).
  • [ISSN] 1535-7732
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Christodoulou M, Ris HB, Pezzetta E: Video-assisted right supradiaphragmatic thoracic duct ligation for non-traumatic recurrent chylothorax. Eur J Cardiothorac Surg; 2006 May;29(5):810-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Chylothorax is an uncommon disorder with respiratory, nutritional and immunological manifestations.
  • Three patients developed chylothorax after chemotherapy and chest irradiation for malignant diseases (lymphoma in two patients and breast cancer in one), one in the context of lymphangioleiomyomatosis, one due to a non-diagnosed lymphoma, and one after heart transplantation.
  • Persistent cessation of chylous effusion within 7 days after surgery was observed in 5/6 patients without recurrence during a mean follow-up time of 41 months.
  • Two patients presented postoperative complications including respiratory insufficiency requiring mechanical ventilation in one, and chylous ascites development requiring peritoneo-venous LeVeen shunting in one patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2006 Nov;30(5):813 [16996746.001]
  • [CommentIn] Eur J Cardiothorac Surg. 2007 Jun;31(6):1148-9; author reply 1149 [17398111.001]
  • (PMID = 16626966.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


81. Shepherd TG, Mujoomdar ML, Nachtigal MW: Constitutive activation of BMP signalling abrogates experimental metastasis of OVCA429 cells via reduced cell adhesion. J Ovarian Res; 2010;3:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Unexpectedly, doxycycline-induced ALK3QD expression in OVCA429 cells reduced tumour implantation on peritoneal surfaces and ascites formation when xenografted into immunocompromised mice by intraperitoneal injection.
  • CONCLUSIONS: We propose that the key steps of ovarian cancer metastasis, specifically cell cohesion of multicellular aggregates in ascites and cell adhesion for reattachment to secondary sites, may be inhibited by overactive BMP signalling, thereby decreasing the ultimate malignant potential of ovarian cancer in this model system.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Jan;286(1):L81-6 [12959928.001]
  • [Cites] Biol Chem. 2003 Jul;384(7):1073-83 [12956424.001]
  • [Cites] Nat Rev Genet. 2003 Oct;4(10):763-73 [14526373.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):740-6 [14644200.001]
  • [Cites] Cell Signal. 2004 Mar;16(3):291-9 [14687659.001]
  • [Cites] Oncogene. 2004 Apr 15;23(17):3024-32 [14691444.001]
  • [Cites] Mol Cancer Res. 2004 Mar;2(3):141-9 [15037653.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):319-30 [15215186.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):159-70 [15324699.001]
  • [Cites] Oncogene. 2004 Oct 7;23(46):7651-9 [15354178.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9326-35 [15531927.001]
  • [Cites] EMBO J. 2004 Dec 8;23(24):4792-801 [15538389.001]
  • [Cites] J Bone Miner Res. 2005 Feb;20(2):330-40 [15647827.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):155-65 [15790452.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):355-66 [15864277.001]
  • [Cites] Oncogene. 2006 Feb 2;25(5):685-92 [16247476.001]
  • [Cites] Mol Cell Biol. 2006 Oct;26(20):7791-805 [16923969.001]
  • [Cites] Carcinogenesis. 2007 Jun;28(6):1153-62 [17272306.001]
  • [Cites] J Cell Physiol. 2007 Dec;213(3):581-8 [17708542.001]
  • [Cites] Biotechnol J. 2008 Oct;3(9-10):1172-84 [18566957.001]
  • [Cites] Gynecol Oncol. 2009 Apr;113(1):143-8 [19135710.001]
  • [Cites] J Ovarian Res. 2009;2:4 [19366455.001]
  • [Cites] Am J Pathol. 2009 Nov;175(5):2184-96 [19808644.001]
  • [Cites] Gynecol Oncol. 1995 Aug;58(2):216-25 [7542622.001]
  • [Cites] Br J Cancer. 1996 Mar;73(5):624-9 [8605097.001]
  • [Cites] Cell. 1996 May 17;85(4):489-500 [8653785.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4427-31 [9331107.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):5022-7 [9371496.001]
  • [Cites] Br J Cancer. 1998 Nov;78(9):1219-23 [9820184.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1525-37 [10329605.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6249-54 [10339573.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):362-7 [10366461.001]
  • [Cites] Biol Cell. 1999 Mar;91(2):131-42 [10399828.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):430-7 [10652437.001]
  • [Cites] Nat Cell Biol. 2000 Feb;2(2):84-9 [10655587.001]
  • [Cites] Curr Opin Cell Biol. 2000 Apr;12(2):235-43 [10712925.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2840-4 [10850425.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2005-11 [10979940.001]
  • [Cites] Blood. 2001 Jan 15;97(2):516-22 [11154231.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2071-80 [11733357.001]
  • [Cites] Oncogene. 2001 Nov 22;20(53):7761-9 [11753654.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1802-15 [12365030.001]
  • [Cites] Ann Surg Oncol. 2002 Nov;9(9):901-6 [12417513.001]
  • [Cites] J Cell Sci. 2003 Feb 1;116(Pt 3):499-511 [12508111.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):277-81 [12543773.001]
  • [Cites] J Bone Miner Res. 2003 Mar;18(3):502-11 [12619935.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8621-3 [12861075.001]
  • [Cites] Endocrinology. 2003 Aug;144(8):3306-14 [12865307.001]
  • [Cites] J Cell Biol. 2003 Sep 15;162(6):1089-98 [12963706.001]
  • (PMID = 20187934.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2838885
  •  go-up   go-down


82. Patriti A, Cavazzoni E, Graziosi L, Pisciaroli A, Luzi D, Gullà N, Donini A: Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy. Surg Laparosc Endosc Percutan Tech; 2008 Aug;18(4):426-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy.
  • A variety of options have been proposed to treat malignant ascites but most of them have failed to reach a significant impact in terms of palliation.
  • Here we present a case of a 49-year-old woman with malignant ascites secondary to peritoneal spreading of a right pleural mesothelioma.
  • A dramatic reduction of ascites was documented in the postoperative period and the patient experienced complete abdominal symptom relief.
  • Ascites did not recur during a follow-up period of 6 months.
  • LHIPEC could be a good therapeutic option to palliate malignant ascites from mesothelioma in cases not eligible for a radical treatment.
  • [MeSH-major] Ascites / therapy. Chemotherapy, Cancer, Regional Perfusion / methods. Laparoscopy. Mesothelioma / pathology. Palliative Care. Peritoneal Neoplasms / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18716551.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


83. Kayacan O, Karnak D, Ayşe Can B, Dizbay Sak S, Beder S: Gastric signet-ring cell adenocarcinoma presenting with left arm deep-vein thrombosis and bilateral chylothorax. Clin Appl Thromb Hemost; 2008 Oct;14(4):476-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abdomen computed tomography revealed abundant ascites and right ovarian enlargement.
  • Pleural fluid cytology showed similar malignant cells.
  • The patient was diagnosed as gastric signet-ring cell adenocarcinoma with endobronchial, mammary, ovarian, pleural, pericardial, peritoneal, and osteal metastases.

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18263634.001).
  • [ISSN] 1076-0296
  • [Journal-full-title] Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • [ISO-abbreviation] Clin. Appl. Thromb. Hemost.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Ströhlein MA, Heiss MM: The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis. Future Oncol; 2010 Sep;6(9):1387-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The trifunctional antibody catumaxomab in treatment of malignant ascites and peritoneal carcinomatosis.
  • Peritoneal carcinomatosis remains an unsolved medical problem in modern oncologic treatment.
  • Excruciating symptoms such as malignant ascites, ileus, nausea, vomiting, dyspnoea and pain deteriorate the quality of life for affected patients.
  • There is still no effective standard treatment for peritoneal carcinomatosis.
  • Intraperitoneal catumaxomab therapy was shown to be the first effective therapy against accumulation of malignant ascites in patients with peritoneal carcinomatosis of epithelial cancer, reducing the need of paracentesis and prolonging puncture-free survival.
  • This paper reviews the mode of action of catumaxomab and analyzes different fields of local immunotherapy in patients with peritoneal carcinomatosis.
  • Catumaxomab is discussed to be an outstanding option for local control and therapy of peritoneal carcinomatosis, which could be an optimal modular therapy in addition to systemic chemotherapy and surgical tumor resection.
  • [MeSH-major] Antibodies, Bispecific / therapeutic use. Antineoplastic Agents / therapeutic use. Ascites / drug therapy. Carcinoma / drug therapy. Peritoneal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20919824.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antineoplastic Agents; 0 / catumaxomab
  •  go-up   go-down


85. Jaaback KS, Ludeman L, Clayton NL, Hirschowitz L: Primary peritoneal carcinoma in a UK cancer center: comparison with advanced ovarian carcinoma over a 5-year period. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:123-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary peritoneal carcinoma in a UK cancer center: comparison with advanced ovarian carcinoma over a 5-year period.
  • The relative incidence of primary peritoneal carcinoma (PPCa) and advanced (FIGO stage III or IV) ovarian serous carcinoma (AOSCa) was assessed over 5 years at a UK cancer center, and the sociodemographic, clinical, and survival data were compared.
  • Similar numbers in both groups had malignant ascites, although 5.8% of patients with AOSCa but none with PPCa had negative cytology.
  • [MeSH-major] Adenocarcinoma / epidemiology. Mixed Tumor, Mullerian / epidemiology. Ovarian Neoplasms / epidemiology. Peritoneal Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515579.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Davidson B, Vintman L, Nielsen S, Reich R, Berner A: Site-related expression of metastasis-associated and signaling molecules in malignant mesothelioma--a new model for the study of tumor biology and disease progression. Lung Cancer; 2005 Jul;49 Suppl 1:S89-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Site-related expression of metastasis-associated and signaling molecules in malignant mesothelioma--a new model for the study of tumor biology and disease progression.
  • [MeSH-minor] Ascites. Cytological Techniques. Disease Progression. Humans. Models, Biological. Neoplasm Metastasis. Neovascularization, Pathologic / metabolism. Pleural Effusion, Malignant / cytology. Receptors, Nerve Growth Factor / biosynthesis. Signal Transduction

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15950809.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Receptors, Nerve Growth Factor
  •  go-up   go-down


87. Abdollahi T, Robertson NM, Abdollahi A, Litwack G: Inhibition of TRAIL-induced apoptosis by IL-8 is mediated by the p38-MAPK pathway in OVCAR3 cells. Apoptosis; 2005 Dec;10(6):1383-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interestingly, while malignant cells are responsive to TRAIL-induced cell death when used alone or in combination with other agents, normal cells do not appear to be sensitive to this ligand, making it a desirable therapeutic compound against many cancers, including many ovarian carcinomas.
  • Interleukin-8 (IL-8), a member of the C-X-C chemokine family, has been found to be at significantly higher level in the ascites from patients with ovarian cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16215677.001).
  • [ISSN] 1360-8185
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATF2 protein, human; 0 / Activating Transcription Factor 2; 0 / Imidazoles; 0 / Interleukin-8; 0 / Isoenzymes; 0 / Pyridines; 0 / RNA, Small Interfering; 0 / SB 203580; 0 / TNF-Related Apoptosis-Inducing Ligand; EC 2.7.1.- / MAP2K3 protein, human; EC 2.7.1.- / MAP2K6 protein, human; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 2.7.12.2 / MAP Kinase Kinase 3; EC 2.7.12.2 / MAP Kinase Kinase 6
  •  go-up   go-down


88. Mishra OP, Kumar R, Ali Z, Prasad R, Nath G: Evaluation of polymerase chain reaction and adenosine deaminase assay for the diagnosis of tuberculous effusions in children. Arch Dis Child; 2006 Dec;91(12):985-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of polymerase chain reaction and adenosine deaminase assay for the diagnosis of tuberculous effusions in children.
  • AIM: To evaluate and compare the utility of polymerase chain reaction (PCR) for the diagnosis of tuberculous effusions in children.
  • METHODS: PCR, adenosine deaminase (ADA) activity and absolute lymphocyte count (ALC) were evaluated in the fluid of 31 tuberculous (20 pleural, 8 ascites and 3 pericardial) and 24 non-tuberculous (10 transudtative ascites, 8 empyema thoracis, 3 malignant pleural and 3 pyopericardium) effusions.
  • CONCLUSION: Fluid PCR alone should not be relied on as a single test; rather, combined analysis with either ADA or ALC could be more useful in the diagnosis of tuberculous effusions in children.
  • [MeSH-major] Adenosine Deaminase / metabolism. Ascites / diagnosis. Empyema, Pleural / diagnosis. Pericardial Effusion / diagnosis. Pleural Effusion / diagnosis. Tuberculosis, Pleural / diagnosis

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Tuberc Lung Dis. 2000 Apr;4(4):361-70 [10777087.001]
  • [Cites] J Med Microbiol. 1997 Feb;46(2):164-9 [9060877.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 2000 Sep;31(3):509-14 [11289011.001]
  • [Cites] Chest. 2001 Jun;119(6):1737-41 [11399699.001]
  • [Cites] Chest. 2003 Sep;124(3):909-14 [12970016.001]
  • [Cites] Br Med J. 1978 Dec 23-30;2(6154):1751-2 [737480.001]
  • [Cites] Acta Med Scand. 1984;215(4):299-304 [6731043.001]
  • [Cites] J Infect Dis. 1990 May;161(5):977-81 [2109022.001]
  • [Cites] Chest. 1990 Jun;97(6):1381-5 [1971783.001]
  • [Cites] Bull World Health Organ. 1990;68(5):571-6 [2289293.001]
  • [Cites] Chest. 1991 Apr;99(4):883-6 [1901261.001]
  • [Cites] J Clin Microbiol. 1993 Aug;31(8):1987-95 [7690367.001]
  • [Cites] J Clin Microbiol. 1993 Aug;31(8):2049-56 [8370729.001]
  • [Cites] Chest. 1994 Apr;105(4):1116-21 [8162735.001]
  • [Cites] Chest. 1996 Feb;109(2):414-9 [8620715.001]
  • [Cites] J Clin Pathol. 1996 Apr;49(4):290-4 [8655703.001]
  • [Cites] J Trop Pediatr. 2000 Oct;46(5):296-300 [11077940.001]
  • (PMID = 16737998.001).
  • [ISSN] 1468-2044
  • [Journal-full-title] Archives of disease in childhood
  • [ISO-abbreviation] Arch. Dis. Child.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.5.4.4 / Adenosine Deaminase
  • [Other-IDs] NLM/ PMC2082988
  •  go-up   go-down


89. Miyake H, Hara I, Yamanaka K, Muramaki M, Gleave M, Eto H: Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential. Oncol Rep; 2005 Feb;13(2):341-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overexpression of insulin-like growth factor binding protein-2 (IGFBP-2) has been shown to be associated with tumor progression in several human malignant tumors; however, the significance of IGFBP-2 expression in bladder cancer remains poorly defined.
  • Furthermore, there was no significant difference in sub-cutaneous tumor growth among KoTCC-1 sublines; however, more advanced tumor progression, including lymph node metastasis and hemorrhagic ascites formation, was observed after the implantation of KoTCC-1/BP2 into the bladder wall of nude mice than after the implantation of KoTCC-1/C.


90. Rahman GA, Abdulkadir AY, Olatoke SA, Uwaezuoke S, Yusuf IF, Braimoh KT: Giant neoplastic omental cyst masquerading as ascites: a case report. Cases J; 2009;2:6482
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant neoplastic omental cyst masquerading as ascites: a case report.
  • Preoperative diagnosis is infrequently made because of lack of characteristic symptoms and signs.
  • CONCLUSION: Neglected omental cysts as in this case may grow to enormous size, undergo malignant transformation and poses serious diagnostic and surgical challenges.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2005 Feb;15(1):33-5 [15714155.001]
  • [Cites] Am J Gastroenterol. 1964 Jan;41:53-7 [14113730.001]
  • [Cites] Radiology. 1987 Aug;164(2):327-32 [3299483.001]
  • [Cites] Ann Trop Paediatr. 2001 Mar;21(1):81-5 [11284253.001]
  • [Cites] Am J Surg. 1970 Jun;119(6):640-5 [5445987.001]
  • [Cites] Z Gastroenterol. 2004 Feb;42(2):153-5 [14963788.001]
  • [Cites] Arch Surg. 1984 Jul;119(7):838-42 [6732494.001]
  • (PMID = 19918526.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2769296
  •  go-up   go-down


91. Sebastian M: Review of catumaxomab in the treatment of malignant ascites. Cancer Manag Res; 2010;2:283-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of catumaxomab in the treatment of malignant ascites.
  • Malignant ascites is frequently found with various solid tumors, and no established treatment options exist, apart from symptomatic paracentesis.
  • Intraperitoneal treatment with catumaxomab resulted in a significant prolongation of puncture-free survival in patients with malignant ascites due to epithelial cancer.
  • Catumaxomab has been approved in Europe for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive epithelial tumors where standard therapy is not available or no longer feasible.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21188120.001).
  • [ISSN] 1179-1322
  • [Journal-full-title] Cancer management and research
  • [ISO-abbreviation] Cancer Manag Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3004584
  • [Keywords] NOTNLM ; ascites / catumaxomab / epithelial cell adhesion molecule
  •  go-up   go-down


92. Koyama S: Coordinate cell-surface expression of matrix metalloproteinases and their inhibitors on cancer-associated myofibroblasts from malignant ascites in patients with gastric carcinoma. J Cancer Res Clin Oncol; 2005 Dec;131(12):809-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coordinate cell-surface expression of matrix metalloproteinases and their inhibitors on cancer-associated myofibroblasts from malignant ascites in patients with gastric carcinoma.
  • However, myofibroblastic invasion remains largely unexplored in malignant ascites.
  • Purpose of this study is to investigate the spatial localization or regulation of matrix metalloproteinases (MMP-2, -7 -9, MT1-MMP) and their inhibitors (TIMP-2 and -4) on myofibroblasts from malignant ascites in 20 patients with gastric carcinoma.
  • CONCLUSION: This study provides the presence of invasive myofibroblasts with activated MMPs in close association with MMPs+ and TIMPs+ cancer cells and tumor-infiltrating lymphocytes from malignant ascites, emphasizing the importance of molecular cross-talk in tumor-host microenvironment for cancer invasion, metastasis and progression.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1999 Jan 1;13(1):35-48 [9887098.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5002-11 [10519415.001]
  • [Cites] Scand J Gastroenterol. 2004 Nov;39(11):1046-53 [15545160.001]
  • [Cites] J Cancer Res Clin Oncol. 1998;124(7):383-8 [9719501.001]
  • [Cites] J Cell Physiol. 1998 Jul;176(1):206-15 [9618160.001]
  • [Cites] Dig Dis Sci. 2000 Apr;45(4):773-80 [10759249.001]
  • [Cites] J Cancer Res Clin Oncol. 1999;125(1):47-54 [10037277.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Feb;128(2):73-9 [11862476.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3097-105 [11595701.001]
  • [Cites] J Pathol. 2003 Jul;200(4):429-47 [12845611.001]
  • [Cites] J Clin Pathol. 2002 Oct;55(10):741-4 [12354798.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Jan;127(1):20-6 [11206267.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10 (19):6579-85 [15475447.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Jul;18(7):763-70 [12795746.001]
  • [Cites] Genes Dev. 2002 Feb 1;16(3):307-23 [11825873.001]
  • [Cites] Cell. 1996 May 31;85(5):683-93 [8646777.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2912-23 [12231536.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Lab Invest. 1990 Aug;63(2):144-61 [2116562.001]
  • [Cites] J Cell Biol. 1993 Jul;122(1):103-11 [8314838.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):273-82 [8686751.001]
  • [Cites] Surgery. 2002 Feb;131(2):129-34 [11854689.001]
  • [Cites] Dig Dis Sci. 2004 Oct;49(10):1621-30 [15573916.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7045-9 [15466198.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):231-4 [14758552.001]
  • [Cites] Dig Dis Sci. 2003 Dec;48(12 ):2290-300 [14714615.001]
  • [Cites] J Cell Biol. 1986 Dec;103(6 Pt 2):2787-96 [3539945.001]
  • [Cites] Oncogene. 2002 Aug 8;21(34):5213-23 [12149643.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):7-13 [12672023.001]
  • [Cites] Am J Pathol. 1992 Aug;141(2):389-96 [1323219.001]
  • (PMID = 16180025.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Matrix Metalloproteinase Inhibitors; 0 / Protease Inhibitors; 0 / Tissue Inhibitor of Metalloproteinases; 0 / tissue inhibitor of metalloproteinase-4; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2
  •  go-up   go-down


93. Nio Y, Iguchi C, Itakura M, Nishi T, Hashimoto K, Takeda H, Takamura M, Omori H, Sato Y, Koike M, Endo S: Placement of an expandable metallic stent improves the efficacy of chemoradiotherapy for pancreatic cancer with malignant portal vein stenosis or obstruction. Anticancer Res; 2009 Aug;29(8):3329-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placement of an expandable metallic stent improves the efficacy of chemoradiotherapy for pancreatic cancer with malignant portal vein stenosis or obstruction.
  • BACKGROUND: Advanced or recurrent pancreatic cancer can sometimes cause obstruction or stenosis of the portal vein (PV), resulting in various symptoms of portal hypertension (PH), such as ascites, pancytopenia, hemorrhagic tendencies and liver dysfunction.
  • PATIENTS AND METHODS: In the present study, 14 patients with malignant portal obstruction due to advanced or recurrent pancreatic cancer received PV stent placement to manage their PH-associated symptoms.
  • In the 3 CR patients, 2 died of carcinomatous ascites 13 and 21 months later, and 1 is still disease free.
  • In the PR and SD patients, pain and PH-associated symptoms such as ascites and hyperglycemia were also improved.


94. Nakai K, Kushikata T, Tose R, Niwa H, Hirota K, Futagami M, Yokoyama Y: [A case of unanticipated postoperative respiratory distress from cancerous pleural effusion]. Masui; 2009 Feb;58(2):195-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of unanticipated postoperative respiratory distress from cancerous pleural effusion].
  • The chest X-ray one week preoperatively demonstrated slight left pleural effusion, but she did not show any dyspnea on preanesthetic interview.
  • Sp(O2) decreased after suction of ascites, but it improved with PEEP Spontaneous respiration developped after the operation, but tidal volume was not enough and respiratory pattern was irregular.
  • The chest X-ray and TEE revealed extended left hemilateral pleural effusion.
  • [MeSH-major] Pleural Effusion, Malignant / complications. Respiratory Distress Syndrome, Adult / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227176.001).
  • [ISSN] 0021-4892
  • [Journal-full-title] Masui. The Japanese journal of anesthesiology
  • [ISO-abbreviation] Masui
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


95. Chen M, Wang WC, Zhou C, Zhou NN, Cai K, Yang ZH, Zhao WF, Li SY, Li GZ: Differentiation between malignant and benign ovarian tumors by magnetic resonance imaging. Chin Med Sci J; 2006 Dec;21(4):270-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between malignant and benign ovarian tumors by magnetic resonance imaging.
  • The odds ratio was even higher when the ancillary finding of peritoneal metastasis or ascites was present.
  • Total 70 ovarian masses were detected by contrast-enhanced MR imaging including 37 malignant ovarian masses and 33 benign ovarian masses with 87% (61/70) accuracy, 86% (32/37) sensitivity, 88% (29/33) specificity, 89% (32/36) positive predictive value, and 85% (29/34) negative predictive value, whereas 70 ovarian masses were detected by unenhanced MR imaging with 74% (52/70) accuracy, 73% (27/37) sensitivity, 76% (25/33) specificity, 77% (27/35) positive predictive value, and 71% (25/35) negative predictive value.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17249204.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


96. Kovacs E: Interleukin-6 leads to interleukin-10 production in several human multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells? Leuk Res; 2010 Jul;34(7):912-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple myeloma (MM) is characterised as a malignant plasma cell proliferation.
  • [MeSH-minor] Ascites / pathology. Bone Marrow / pathology. Cell Division / drug effects. Cell Line, Tumor / drug effects. Humans. Lymph Nodes / pathology. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Paracrine Communication. Pleura / pathology. Receptors, Interleukin-6 / biosynthesis. Receptors, Interleukin-6 / drug effects. Receptors, Interleukin-6 / genetics. Recombinant Proteins / pharmacology

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19762082.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / IL10 protein, human; 0 / IL6 protein, human; 0 / Interleukin-6; 0 / Neoplasm Proteins; 0 / Receptors, Interleukin-6; 0 / Recombinant Proteins; 130068-27-8 / Interleukin-10
  •  go-up   go-down


97. Chang H, Sun CF: Detection of B cell lymphoma involvement in T cell-rich serous fluid by immunoglobulin gene rearrangement: a report of 2 cases. Acta Cytol; 2008 Mar-Apr;52(2):231-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytology of the effusion is equivocal for lymphoma involvement.
  • CASES: We report 2 cases of diffuse large B cell lymphoma with massive lymphocyte predominant serous fluid, ascites in one case and pleural effusion in the other.
  • Lymphoma involvement of effusion was confirmed by immunoglobulin gene rearrangement detected by polymerase chain reaction.
  • CONCLUSION: Our case demonstrated the value of gene rearrangement study in establishing diagnosis of equivocal cases.
  • [MeSH-major] Ascitic Fluid / immunology. Gene Rearrangement, B-Lymphocyte. Immunoglobulins / genetics. Lymphoma, Large B-Cell, Diffuse / diagnosis. Pleural Effusion, Malignant / immunology. T-Lymphocytes / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500002.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulins
  •  go-up   go-down


98. Linke R, Klein A, Seimetz D: Catumaxomab: clinical development and future directions. MAbs; 2010 Mar-Apr;2(2):129-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Catumaxomab, a monoclonal bispecific trifunctional antibody, was approved in the European Union in April 2009 for the intraperitoneal treatment of patients with malignant ascites.
  • It is the first substance worldwide with a regulatory label for the treatment of malignant ascites due to epithelial carcinomas.
  • Catumaxomab is able to destroy EpCAM positive tumor cells in the peritoneal cavity known as the main cause of malignant ascites.
  • [MeSH-major] Antibodies, Bispecific / pharmacology. Antineoplastic Agents / pharmacology. Carcinoma / drug therapy. Immunotherapy. Peritoneal Neoplasms / drug therapy


99. Jandu N, Richardson M, Singh G, Hirte H, Hatton MW: Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property. Int J Gynecol Cancer; 2006 Jul-Aug;16(4):1536-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property.
  • Ovarian cancer ascites fluid (OCAF) displayed an antiangiogenic property in a chick chorioallantoic membrane (CAM) assay.
  • Recently, immunopurified fibrin(ogen) degradation products (FDPs) from malignant effusions of VX2 tumor-burdened rabbits exhibited antiangiogenic activity on the CAM.
  • Collectively, these FDPs contributed to the net antiangiogenic property of ascites fluid.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Ascitic Fluid / metabolism. Fibrin / metabolism. Fibrin Fibrinogen Degradation Products / pharmacology. Neovascularization, Pathologic / prevention & control. Ovarian Neoplasms / metabolism. Pleural Effusion / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16884362.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Fibrin Fibrinogen Degradation Products; 9001-31-4 / Fibrin; EC 3.4.21.7 / Fibrinolysin
  •  go-up   go-down


100. Eymin G, Andresen M, Godoy J, Rada G: [Malignant neuroleptic syndrome and polyserositis associated to clozapine use: report of one case]. Rev Med Chil; 2005 Oct;133(10):1225-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant neuroleptic syndrome and polyserositis associated to clozapine use: report of one case].
  • [Transliterated title] Síndrome neuroléptico maligno y poliserositis en paciente usuaria de clozapina: una asociación infrecuente.
  • Malignant neuroleptic syndrome is a complication of antipsychotic medication use.
  • An abdominal CAT scan showed ascites and pleural effusion.
  • [MeSH-major] Antipsychotic Agents / adverse effects. Clozapine / adverse effects. Neuroleptic Malignant Syndrome / etiology
  • [MeSH-minor] Adolescent. Bipolar Disorder / drug therapy. Female. Humans

  • Genetic Alliance. consumer health - Neuroleptic malignant syndrome.
  • Hazardous Substances Data Bank. CLOZAPINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16341374.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Antipsychotic Agents; J60AR2IKIC / Clozapine
  •  go-up   go-down






Advertisement